

Review

Medicinal plants in the space exploration era: challenges and perspectives

Francesca Pettinau ^{1,2*} and Alessandro Orrù ^{1,*}

¹ Institute of Translational Pharmacology, National Research Council of Italy, Parco Scientifico e Tecnologico della Sardegna, 09050 Pula, Italy

² Department of Chemical and Geological Sciences, University of Cagliari, 09042 Cagliari, Italy

*Francesca Pettinau and Alessandro Orrù equally contributed to this work.

Correspondence:

FP francesca.pettinau@ift.cnr.it, francesca.pettinau@unica.it

AO alessandro.orrù@ift.cnr.it

Academic Editor: Firstname Last-name

Received: date

Revised: date

Accepted: date

Published: date

Citation: To be added by editorial staff during production.

Copyright: © 2025 by the authors.

Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Table S1. Milestones in the history of space travel.

32

Date	Event	Agency/Country
20 June 1944	Launch of the V-2 rocket, the first human-made artificial object to reach outer space by crossing the Karman line.	Germany
24 October 1946	First picture of the Earth taken from outer space by a camera installed in the V-2 No. 13 rocket.	U.S.A.
04 October 1957	Launch of the Sputnik-1, the first artificial satellite.	Soviet Space Program, URSS
03 November 1957	Launch of the Sputnik-2, the first satellite with a living animal on board (the dog Layka).	Soviet Space Program, URSS
12 September 1959	Launch of the Luna-2, the first spacecraft hard-landing the surface of a celestial body (Moon).	Soviet Space Program, URSS
12 April 1961	Launch of the Vostok-1, the first spacecraft with a human being on board. Jurij Alekseevič Gagarin was the first human to reach the outer space and orbit Earth.	Soviet Space Program, URSS
16 June 1963	Launch of the Vostok-6, the first spacecraft with a woman on board. Valentina Tereškova was the first woman to reach the outer space and orbit Earth.	Soviet Space Program, URSS
26 July 1963	Launch of Syncom-2, the first telecommunications satellite to operate in geosynchronous orbit.	NASA, U.S.A
15 July 1965	Mariner-4 was the first spacecraft to transmit the picture of the surface of another planet (Mars).	NASA, U.S.A
21 December 1968	Launch of the Apollo-8, the first crewed spacecraft to leave Earth's orbit, to reach and orbit Moon and to safely return to Earth. Frank Borman, James Lovell, and William Anders were the first humans to see the far side of the moon and to take a picture of Earthrise.	NASA, U.S.A
16 July 1969	Launch of the Apollo-11, the first crewed spacecraft to land on Moon's surface. Neil Armstrong and Buzz Aldrin were the first humans to step onto Moon's surface.	NASA, U.S.A
17 August 1970	Launch of the Venera-7, the first spacecraft to soft-land on another planet (Venera) and to transmit back data to Earth.	Soviet Space Program, URSS

Date	Event	Agency/Country
12 September 1970	Launch of the Luna-16, the first remote-controlled spacecraft to carry back lunar samples.	Soviet Space Program, URSS
19 April 1971	Launch of the Salyut-1, the first space station.	Soviet Space Program, URSS
28 May 1971	Launch of the Mars-3, the first spacecraft to soft-land the Mars's surface.	Soviet Space Program, URSS
30 May 1971	Launch of the Mariner-9, the first spacecraft to orbit Mars and to transmit images of its satellite (Phobos and Deimos).	NASA, U.S.A
06 June 1971	Launch of the Soyuz-11 with three cosmonauts on board: Georgij Timofeevič Dobrovolskij Viktor Ivanovič Pacaev and Vladislav Nikolaevič Volkov. It represented the first crew to live and work in a space station (about 3 weeks). The cosmonauts tragically died for a technical problem while preparing the re-entry. To this day, they remain the only humans to have lost their lives in space.	Soviet Space Program, URSS
14 May 1973	Launch of the Skylab, the first and only space station exclusively operated by the United States.	NASA, U.S.A
20 August 1975	Launch of the Viking 1, the spacecraft that transmitted the first image of the Mars's surface.	NASA, U.S.A
12 April 1981	First flight of the Space Shuttle Program. The space shuttle Columbia was the first reusable spacecraft in the story of space travel. The Columbia, with two astronauts on board, returned to Earth two days later.	NASA, U.S.A
02 July 1985	Launch of the Giotto, the first spacecraft to fly-by a comet (Halley's comet).	ESA, Europe
19 February 1986	Launch of the core module of the modular space station Mir. Mir was the first continuously inhabited space station in orbit; it remained operational until 23 March 2001 when it was deorbited.	Soviet Space Program, URSS

Date	Event	Agency/Country
18 October 1989	Launch of the Galileo spacecraft. It was the first spacecraft to orbit Jupiter (it arrived at the planet on 7 December 1995) and to launch an atmospheric probe in its atmosphere.	NASA, U.S.A
17 February 1996	Launch of the Eros, the first spacecraft to orbit (14 February 2000) and soft-land (12 February 2001) on a near-Earth asteroid (Eros).	NASA, U.S.A
15 October 1997	Launch of the Cassini-Huygens, the first spacecraft to orbit Saturn (with the orbiter Cassini, 01 July 2004) and to soft-land on the surface's satellite of a planet other than Earth (Saturn's moon Titan, with the lander Huygens, 14 January 2005).	NASA (U.S.A), ESA (Europe), ASI (Italy)
20 November 1998	Launch of the first module of the International Space Station. The ISS is the largest space station ever built and is currently operational.	NASA (U.S.A.), Roscosmos (Russia), ESA (Europe), JAXA (Japan), and CSA (Canada)
9 May 2003	Launch of the Hayabusa, the first spacecraft to return to Earth, seven years later, with soil samples from an asteroid (the asteroid 25143 Itokawa).	JAXA, Japan
2 March 2004	Launch of the Rosetta-Philae (orbiter-lander), the first spacecraft to orbit a comet (6 August 2014, comet 67P/Churyumov-Gerasimenko) and to land in its surface (12 November 2014).	ESA, Europe
11 May 2004	Launch of the Messenger, the first spacecraft to orbit Mercury (18 March 2011)	NASA, U.S.A
21 June 2004	First sub-orbital flight of privately funded spacecraft (SpaceShipOne). The pilot of the flight was Mike Melvill.	Scale Composites, U.S.A.
19 January 2006	Launch of the New Horizons, the first spacecraft to fly-by Pluto and Charon (14 July 2015), the largest of its satellites. On first January 2019, the New Horizons fly-bys 486958 Arrokoth, the farthest object in the solar system explored by a spacecraft.	NASA, U.S.A

Date	Event	Agency/Country
27 September 2007	Launch of the Dawn, the first spacecraft to orbit a dwarf planet (Ceres, 6 March 2015)	NASA, U.S.A
21 December 2015	First vertical landing of an orbital-class rocket booster. It allows the booster to be reused reducing launches' cost.	SpaceX, U.S.A.
03 January 2019	First landing of a spacecraft on the far side of the Moon.	CMSA, China
10 February 2020	Launch of SoLO, the first solar orbiter developed to provide close-up views of the Sun, including its poles, and to study the solar activity.	ESA (Europe), NASA (United States),
30 May 2020	SpaceX Demo-2, the first private crewed test flight to the ISS aboard the Crew Dragon spacecraft.	SpaceX, U.S.A.
29 April 2021	Launch of the first module of the Tiangong, a space station constructed by China. It is currently operational.	CMSA, China
16 September 2021	Inspiration-4, the first orbital spaceflight with only private citizens aboard.	SpaceX, U.S.A.
8 April 2022	Axiom Mission 1, the first all-private astronaut mission to the ISS	Axiom Space (U.S.A.), SpaceX (U.S.A.)
23 March 2023	Launch of Terran 1, the first two-stage small-lift launch vehicle almost completely 3D-printed.	Relativity Space, U.S.A
23 August 2023	Soft landing of Chandrayaan-3 (with the lander Vikram). India became the fourth country to do a soft lunar landing, and the first to reach the lunar south polar region.	ISRO, India
03 May 2024	Launch of Chang'e-6, first robotic mission to retrieve samples from the far side of the Moon (25 June 2024).	CMSA, China

33

34

35

36

37

4.1. Therapeutic Potential of Phytochemicals in Space Medicine 38

4.1.1 Use of medicinal plants as alternative medication for sleep disorders 39

Valeriana officinalis L., commonly known as valerian, is a perennial herb belonging to the Caprifoliaceae family and represents the most studied medicinal plants for managing sleep disorders [1]. Besides the hypnotic effect, the root extract of valerian exhibits antioxidant, antimicrobial, anti-inflammatory, sedative, anxiolytic, spasmolytic, anticonvulsant, cytoprotective, and neuroprotective activities [2]. Valerian root extract (VE) has a complex composition [3], but its hypnotic action appears to be attributable to valerenic acid, a bicyclic sesquiterpenoid. Valerenic acid enhances GABAergic neurotransmission directly by acting as a positive allosteric modulator of specific GABA-A receptor subpopulations [4], and indirectly by inhibiting the catabolism of gamma-aminobutyric acid (GABA) [5]. Numerous clinical studies have been conducted over time to demonstrate the efficacy of VE in improving sleep disorders. These studies have yielded conflicting results, likely due to differences in the extract, dosage, timing of administration, and inclusion criteria for the trial subjects [6,7]. However, a recent review of randomised controlled trials, conducted in patients with a diagnosis of insomnia, revealed an overall improvement of symptoms following administration of VE [1]. In comparative clinical studies, the efficacy for VE was comparable to that of the benzodiazepine oxazepam [8,9]. Interestingly, the hypnotic effects of VE have been also observed testing poli-herbal preparation containing hop [10,11] or hop and passiflora [12]. In all clinical studies VE was found to be safe and well tolerated. 40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Crocus sativus L. is a medicinal herb belonging to the Iridaceae family that has been widely studied for its promising beneficial effects on neurological and neuropsychiatric disorders [13]. The pharmacologically active part of the plant is represented by the stigmas of the flower which, once dried, take the name of saffron [13]. Saffron is reach of pharmacologically active ingredients, and among them the most relevant are crocin, safranal and picrocrocin [14]. Saffron has antioxidant and anti-inflammatory activity [15], and evidence exists showing its ability to modulate serotonin, dopamine, norepinephrine and glutamate neurotransmission [16]. Based on these pharmacological effects, saffron has been studied as potential treatment for anxiety, depression, epilepsy and neurodegenerative diseases [13]. Furthermore, several meta-analyses of available clinical studies have highlighted the ability of saffron treatment to improve insomnia symptoms without causing significant adverse events [17–19]. Evidence exists suggesting that this effect may be mediated by the interaction of safranal with the benzodiazepine site in the GABA-A receptor [20]. 57
58
59
60
61
62
63
64
65
66
67
68

Lavandula angustifolia Mill. (synonym of *Lavandula officinalis* Chaix), commonly known as lavender, is an evergreen shrub belonging to the Lamiaceae family. Lavender essential oil (LavEO) is recognized for its potential therapeutic activity, mainly including relief from pain, stress, anxiety, and insomnia [21]. The essential oil contains about 100 compounds, and among them, the monoterpenes linalool (25%–46%) and linalyl acetate (20%–45%) are the most abundant [22]. In most clinical studies, the predominant route of administration of LavEO is inhalation, and the treatment is therefore called aromatherapy [21]. Therapies based on the inhalation of aromatic essences of plant origin are enjoying increasing success, not only for the treatment of sleep disorders but more generally for promoting general well-being [23,24]. The rationale behind the effectiveness of aromatherapy is based on the hypothesis that inhaling aromatic oils positively modulates human emotions and physiological functions through the activation of limbic structures following stimulation of the olfactory system [23,24]. Furthermore, specific components in essential oils can modulate specific neurotransmission, inflammatory, or endocrine pathways [25]. Recent studies have revealed that inhaling LavEO improves several aspects of sleep disorders, while also reducing stress, anxiety and depression [26–29]. In addition to its effectiveness in aromatherapy, LavEO retains its hypnotic activity even when taken orally. Specifically, Silexan, a patented standardized LavEO for oral use, 69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84

ameliorated insomnia because of its anxiolytic effect in patients suffering from anxiety disorders [30–33]. The exact mechanism underlying the hypnotic activity of LavEO has not been fully elucidated. Lavender is known to exert a general depression on neural activity independently of its interaction with the GABA-A receptor (where, in fact, it acts as a receptor antagonist) [34]. Furthermore, lavender-induced sleep improvement in anxious patients appears to be based on its potentiation of serotonin 5-HT_{1A} receptors [35] and concomitant inhibition of voltage-gated calcium channels [36].

Melissa officinalis L., commonly known as lemon balm, is a perennial herbaceous plant belonging to Lamiaceae family. Folk medicine claims the use of lemon balm as calming agent and to ameliorate digestive tract disturbance [37]. Several studies confirm the potential therapeutic value of lemon balm demonstrating its antioxidant and anti-inflammatory properties [38]. Furthermore, lemon balm extract has been found to elicit positive effects on the central nervous system; it has beneficial effects on anxiety and depression, improves cognitive performance and has neuroprotective activity [37]. Phytochemical studies revealed that lemon balm extract is rich in pharmacological active ingredients such as volatile compounds, triterpenes, phenolic acids, and flavonoids [39]. Clinical trials investigating the ability of lemon balm to manage sleep disturbances have produced promising but conflicting results, with some of them showing an improvement of sleep quality and quantity [40–44] while other investigation failed to detect significant effects [45,46]. The poor bioavailability of some active compounds in lemon balm may be the cause of this lack of reproducibility. This is confirmed by a recent clinical study in which insomnia was successfully treated using a phytosomal formulation of standardized lemon balm extract, which aimed to increase the bioavailability of the active polyphenolic components [47]. The beneficial effects of lemon balm on sleep appear to be mediated, at least in part, by rosmarinic acid through direct stimulation of GABA-A receptors [48] and indirect enhancement of GABAergic transmission secondary to inhibition of GABA transaminase [49].

4.1.2 Use of medicinal plants as alternative medication for pain

Capsicum annum L. (Ca) is an herbaceous plant belonging to Solanaceae family. There are several species of the *Capsicum* genus whose domestication dates back approximately 6,000 years, but Ca is the most widely cultivated and economically important for both culinary and medicinal uses. Available preclinical in vitro and in vivo studies attribute numerous pharmacological activities to Ca fruits or its components, such as antioxidant, anti-inflammatory, antifungal, antimicrobial, gastroprotective, antihyperlipidemic and immunomodulatory activities, which may explain its uses in traditional medicine [50]. The broad pharmacological spectrum of Ca reflects its complex phytochemical composition including several classes of bioactive compounds: carotenoids, phenolic acids, flavonoids, saponins, capsaicinoids, vitamins (C, E, and A), and volatile molecules [50]. Among them capsaicin is the most important pharmacologically active compound. For pain management Ca or capsaicin has been commonly applied topically in the form of patches, gels or creams. Several clinical studies have highlighted the ability of Ca plasters to effectively relieve various forms of pain such as low back pain [51–53] chronic soft tissue pain [53] and post-surgery pain [54]. The efficacy of Ca plasters was also confirmed by studies showing that Ca plaster use can reduce postoperative analgesics requirement [55,56]. These promising results have been confirmed and extended by clinical studies investigating the analgesic activity of topical applications of capsaicin in patients suffering from acute and chronic pain [57–59]. Ca and capsaicin topical application was reported as being safe and well-tolerated, with no systemic toxicity. The most reported side effects, including erythema, pain, itching, burning, and edema, are limited to the application site and depend on the concentration of capsaicin [60]. The analgesic effect of capsaicin is mediated by the transient receptor potential cation channel subfamily V member 1 receptor (TRPV1r). Prolonged exposure to capsaicin activates TRPV1r on nociceptors triggering a cascade of events including an initial allodynia followed

by defunctionalization of TRPV1r and consequent ablation of nociceptive afferents resulting in sustained reduction of pain perception [61]. This process is reversible but has the therapeutic advantage that a single exposure to capsaicin for a short period of time (30-60 minutes) provides pain relief that can last weeks (up to three months in some clinical studies) [58,60].

Curcuma longa L., also known as turmeric, is a perennial, rhizomatous, herbaceous plant belonging to Zingiberaceae family. The root, a large cylindrical and branched rhizome, is the part of the plant of greatest interest both to produce spices and for its medicinal value. Turmeric has been used for centuries in various traditional medical systems, mainly in India, Egypt and China for wound healing and to alleviate gastrointestinal problems and inflammatory diseases [62]. The medical use that has been made of it in folk medicine is justified, at least in part, by studies showing that turmeric has antioxidant, anti-inflammatory, antimicrobial, anti-diabetic and hepatoprotective activity [62,63]. The main classes of bioactive compounds found in turmeric rhizome are essential oils (sesquiterpenoids, monoterpenoids and norsesquiterpenoids) and curcuminoids (curcumin, demethoxycurcumi, and bisdemethoxycurcumin) [64]. Curcumin, the main component of turmeric, has low water solubility and poor bioavailability which requires its use in high doses. Furthermore, several strategies have been developed to improve the bioavailability of curcumin, such as the inclusion of the turmeric extract in liposomes, polymeric micelles, microemulsions, and nanoparticles, or its combination with natural additives such as piperidine, genistein, and essential oils normally present in the turmeric rhizome [64]. Several recent clinical studies agree that turmeric treatment relieves joint pain and improves joint function in patients with knee osteoarthritis, regardless of the specific preparation used [65–67]. A synergistic analgesic effect was also noted combining turmeric extract with diclofenac suggesting its potential use in adjuvant therapies [68–71]. Interestingly, preliminary clinical studies suggest that turmeric extract, in combination with *Boswellia serrata* extract, could be a promising natural alternative also for low back pain [72,73] and musculoskeletal pain [74] relief. Overall, turmeric extracts were safe and well-tolerated with no evidence of severe adverse effects. Taken together, preclinical and clinical studies suggest that turmeric may mitigate pain specifically in conditions where inflammation and oxidative stress play a key role. Therefore, turmeric is believed to exert an analgesic activity by its antioxidant activity and by inhibiting several pro-inflammatory mediators and the production of inflammatory [69,75–77].

Zingiber officinale Roscoe, commonly known as ginger, is an herbaceous perennial plant belonging to Zingiberaceae family. Like turmeric, ginger rhizome is consumed as a spice and used for its potential medicinal effects. Ginger is a common remedy used in traditional Eastern medical systems to treat cold, cough, nausea, gastrointestinal problems, pain, and arthritis [78–80]. The use of ginger in ethnomedicine is supported by a large body of preclinical evidence demonstrating that ginger extract has anti-inflammatory, antioxidant, gastroprotective and hepatoprotective activities, among others [81]. Bioactive compounds are abundant in ginger extract, mainly phenolic (gingerols, shogaols, paradols, zingerone) and terpene (zingiberene, α -curcumene, β -sesquiphellandrene) compounds [82]. Several meta-analyses have been conducted that have provided clear confirmation that ginger extract can relieve pain associated with osteoarthritis [83], dysmenorrhea [84], and migraine [85]. Furthermore, promising clinical data are emerging showing the potential analgesic activity of ginger extract in joint [86] and muscle [87] pain. Ginger extract was well tolerated, with mild and transient adverse effects reported (predominantly gastrointestinal). The analgesic effect of ginger extract results from the synergy of several mechanisms of action. The analgesic effect of ginger extract appears to result from the synergy of multiple mechanisms of action [88,89]: 1) the inhibition of the release of proinflammatory factors; 2) a free radical scavenging activity; 3) the activation of TRPV1 receptors; 4) the activation of specific subpopulations of serotonin receptors (5-HT₁, 5-HT₃ and 5-HT₅). Interestingly, ginger's ability to relieve pain by inhibiting the release of inflammatory markers has recently been confirmed in clinical settings [86].

Salix is a genus of plants, generally known as willow tree, belonging to Salicaceae family. The healing properties of willow trees have crossed time and space, having been known in virtually all cultures around the world [90]. The analgesic and anti-inflammatory properties of willow leaf extract were already known to the Sumerians and in ancient Egypt but was only in the 1824 that salicin (an alcoholic β -glucoside) was extracted from *Salix alba* bark and identify as its main bioactive component by Francesco Fontana and Bartolomeo Rigatelli [91,92]. Although research on salicin led to the synthesis of acetylsalicylic acid (Felix Hoffman, 1897), the therapeutic use of willow bark extract continues to arouse interest. Contrary to what one might expect, in fact, the mechanisms of action and adverse effects of aspirin and willow bark extract have little in common. In addition to salicin, willow bark extract contains other bioactive compounds (flavonoids, proanthocyanidins, and tannins) [93]; moreover, salicin is per se inactive and only a fraction of it is metabolized into biologically active salicylate derivatives [94]. Consequently, the analgesic and anti-inflammatory effects of willow bark result from the synergy of multiple mechanisms of action. Finally, willow bark extract has a better side-effects profile since, unlike aspirin, it does not damage the gastrointestinal mucosa and does not affect blood clotting [95]. Consistently, clinical studies have provided promising, though not conclusive, results in favor of the use of willow bark extract in the treatment of low back pain [96–98] and osteoarthritis [99].

Harpagophytum procubens (Burch.) DC. ex Meis and **Harpagophytum zeyheri Decne.** (collectively composed of 5 subspecies), known as devil's claw, are perennial tuberous herbs belonging to the Pedaliaceae family that share the same pharmacological properties [100]. Devil's claw is native to Southern Africa, particularly the Kalahari Desert region, where its secondary tubers have been used for centuries in the local traditional medical systems. People used to prepare oral or topic formulations for the management of various types of pain (headache, toothache, heartburn, back-, menstrual-, muscular and joint pain), digestive disorders, fever and skin problems (burns, sores and boils) [101,102]. A growing body of preclinical in vitro and in vivo evidence has been gathered over-time to support the applications in folk medicine, demonstrating that devil's claw root extract or its main components have antioxidant, anti-inflammatory, analgesic, antimicrobial and anti-diabetic activity [101]. Phytochemical analysis revealed that devil's claw extract contains a variety of bioactive compounds responsible for its pharmacological effects, including iridoid glycosides (harpagoside, harpagide, procumbide, 8-O-p-Coumaroylharpagide), phenolic glycosides, flavonoids and triterpenes [102]. Clinical studies have further contributed to highlighting the promising analgesic activity of devil's claw extract specifically on low back pain [103] and osteoarthritis [104]. Devil's claw has also demonstrated an effectiveness level similar to that of authorized anti-inflammatory drugs [105–107]. There were no reports of serious adverse effects; the majority were gastrointestinal in nature and ranged from mild to moderate in severity. While the precise mechanism behind the analgesic effect of devil's claw extract remains unclear, its capacity to reduce oxidative stress and inhibit proinflammatory mediators and pathways likely contribute to its pain-modulating properties in inflammatory conditions [101]. Finally, a recent investigation underscored the involvement of the cannabinoid system in devil's claw activity, evidenced by enhanced CB2 receptor expression and suppression of endocannabinoid turnover [108].

Boswellia serrata Roxb is a deciduous tree belonging to Burseraceae family, native to India, the Arabic peninsula, the horn of Africa and west Africa [109]. An oleo-gum resin known as Indian frankincense is derived from the bark of the tree and has been traditionally used in Ayurvedic and Unani medical systems to treat a range of ailments. Specifically, historical records describe the use of *B. serrata* resin (Bsr) in the management of inflammatory diseases and wound healing, with its psychoactive effects also noted in traditional use [110]. Modern scientific interest in its therapeutic potential began to intensify in the late 20th century, when researchers isolated boswellic acid (a pentacyclic triterpene) and its derivatives, which represent the main bioactive constituents responsible for its anti-inflammatory effects [111]. Clinical studies are now helping to confirm and

strengthen anecdotal and preclinical scientific evidence. Meta-analysis studies have in fact reported encouraging results specifically in the treatment of osteoarthritis [112,113], suggesting a favorable safety profile and therapeutic potential of Bsr in inflammatory-based diseases. *B. serrata* is also a valuable component in poly-herbal formulations with analgesic and anti-inflammatory activity [72–74,114]. As for the mechanism of action, the anti-inflammatory activity of *B. serrata* is expressed through the inhibition of 5-lipoxygenase (an enzyme crucial for the synthesis of leukotrienes) [111,115]. Moreover, *B. serrata* extract exhibits synergistic activity through additional mechanisms, including inhibition of human leukocyte elastase and reduction of oxidative stress [115,116]. Overall, unlike conventional nonsteroidal anti-inflammatory drugs (NSAIDs), Bsr reduce leukotriene synthesis while sparing prostaglandins and minimizing gastrointestinal toxicity.

4.1.3 Use of medicinal plants as alternative medication for space motion sickness (see main text) 240

241

4.1.4 Use of medicinal plants as alternative medication for skin diseases 242

Aloe vera (L.) Burm. f., belonging to the Asphodelaceae family, is a perennial succulent plant widely distributed in tropical and subtropical regions. Its use in traditional medicine dates back thousands of years for the treatment of burns, wounds, and various skin disorders [117]. The plant contains two major constituents with distinct chemical compositions: the gel obtained from the inner parenchymal tissue and the latex collected from the outer cortex [118]. A specific set of anthraquinones is responsible for the laxative, irritant, and allergenic effects of latex. Therefore, the manufacturing processes for aloe products focus on gel extraction, minimizing latex contamination. The gel extracted from the inner parenchyma of the leaves contains a complex mixture of polysaccharides (notably acemannan), anthraquinones, enzymes, vitamins, minerals and amino acids responsible for its pharmacological activity [118]. Preclinical studies have demonstrated *A. vera*'s potent wound-healing, anti-inflammatory, and antimicrobial properties, mediated through enhanced fibroblast proliferation, collagen synthesis, and antioxidant activity [119,120]. Several clinical studies have confirmed that topical formulations containing *A. vera*, alone or in combination with other natural products, accelerate wound healing, reduce erythema, and relieve itching in patients with burns, psoriasis, or radiation-induced dermatitis [121,122]. Interestingly, oral administration of *A. vera* sterols has been demonstrated to improve skin hydration and elasticity, thereby promoting healthy skin [123,124]. Moreover, *A. vera* extracts have shown bacteriostatic activity against *Staphylococcus aureus* and *Pseudomonas aeruginosa*, supporting their role in infection control [125]. Topical *A. vera* preparations are generally safe and well tolerated, with rare cases of hypersensitivity or contact dermatitis reported. The beneficial effects of *A. vera* on skin are largely attributed to several mechanisms such as the ability to scavenge free radicals, to modulate inflammatory and immunomodulatory mediators and to promote re-epithelialization [120,126].

Curcuma longa L. In addition to what is described above, turmeric exhibits a valuable activity in various dermatological disorders including acne, psoriasis, eczema, and photo-aging by virtue of its potent anti-inflammatory, antioxidant, antimicrobial, and wound-healing effects [127]. Clinical and experimental studies have shown that topical or oral curcumin formulations can reduce skin inflammation, enhance collagen deposition, and promote re-epithelialization in chronic wounds [128–130]. Turmeric is generally well tolerated, although contact dermatitis and mild irritation have been reported with concentrated topical preparations [131]. Its therapeutic benefits are primarily attributed to the modulation of oxidative and inflammatory pathways, particularly through inhibition of the NF- κ B signaling cascade and activation of Nrf2 antioxidant responses [132,133].

Calendula officinalis L. (Asteraceae), commonly known as marigold, is an annual herb native to the Mediterranean region and widely used in traditional and modern phytotherapy for its skin-healing

properties [134]. The flowers contain triterpenoids, flavonoids, saponins, carotenoids, and essential oils, which contribute to its anti-inflammatory, antioxidant, antimicrobial, anti-fungal, anti-cancer and analgesic effects [135–137]. Calendula extracts have demonstrated strong wound-healing activity in both preclinical and clinical models, primarily through the stimulation of angiogenesis, granulation tissue formation, and collagen metabolism [134]. Topical *C. officinalis* ointments and gels have shown efficacy in accelerating wound closure and reducing erythema and swelling in patients with burns, ulcers, and post-radiation dermatitis [138,139]. Mechanistically, Calendula's activity is attributed to the inhibition of cyclooxygenase and lipoxygenase pathways, coupled with increased antioxidant enzyme expression and collagen synthesis [140].

***Camellia sinensis* (L.) Kuntze**, the tea plant, is an evergreen shrub belonging to Theaceae family native to China and Southeast Asia. Tea has a thousand-year history as a beverage and is currently consumed by around 3 billion people worldwide, making it one of the most popular non-alcoholic drinks globally. In the traditional Chinese and Indian medical systems tea has been used for its stimulant, diuretic, and cardioprotective activities, as well as for wound healing [141]. Six main types of tea exist, defined by the processing method and the degree of oxidation of the leaves of *C. sinensis* plant: white, green, yellow, oolong, black, and dark (or post-fermented) tea [142]. Its leaves are rich in polyphenols—especially catechins such as epigallocatechin gallate (EGCG)—which possess strong antioxidant, anti-inflammatory, and photoprotective properties [143–145]. Purine alkaloids (mainly caffeine) are another relevant class of bioactive compounds found in *C. sinensis* leaves [144,145]. Numerous studies have reported that topical or oral administration of *C. sinensis* extracts can improve skin barrier function, prevent UV-induced oxidative damage, and alleviate symptoms of psoriasis, atopic dermatitis, and acne [146]. Clinical trials have shown that green tea-based creams reduce sebum production and lesion count in acne patients [147]. Moreover, EGCG has been shown to inhibit keratinocyte hyperproliferation and modulate inflammatory mediators such as IL-8 and TNF- α , which are key factors in psoriatic lesions [148]. *Camellia sinensis* formulations are generally safe and well tolerated, with no major adverse effects reported. Its protective and restorative effects on the skin are mainly due to its potent antioxidant capacity, suppression of proinflammatory cytokines, and regulation of skin immune responses [149,150].

***Hypericum perforatum* L.**, commonly known as St. John's wort, is a perennial herb belonging to the family Hypericaceae, native to Europe, North Africa, and Western Asia but now distributed worldwide [151]. It has been used for centuries in traditional medical systems for the treatment of wounds, burns, neuralgias, and mood disorders [152]. The aerial parts of *H. perforatum* contain a complex mixture of bioactive compounds, among which naphthodianthrones (hypericin), phloroglucinols (hyperforin), and various flavonoids (rutin, quercetin, hyperoside) are the most pharmacologically relevant [153,154]. These constituents exhibit antioxidant, anti-inflammatory, antimicrobial, anti-cancer and antidepressant properties that have been confirmed in numerous preclinical and clinical studies [153,155]. In addition, topical formulations of *H. perforatum* extract have been reported to improve symptoms of atopic dermatitis, mild plaque psoriasis, herpes virus and surgical or burn wounds, largely by modulating inflammatory mediators such as TNF- α and IL-6 and promoting keratinocyte differentiation, re-epithelialization, angiogenesis, wound contraction, and connective tissue regeneration [155–159]. The therapeutic effects of *H. perforatum* preparations on the skin are attributed to several mechanisms such as the ability to reduce oxidative stress, to modulate the expression of inflammatory mediators, and to promote keratinocyte differentiation, re-epithelialization, angiogenesis, wound contraction, and connective tissue regeneration [160]. When used topically, *H. perforatum* preparations are generally safe and well tolerated, though photosensitivity and mild irritation have been occasionally reported [160].

4.1.5 Potential use of adaptogens to increase resilience

323

Panax ginseng Meyer is a perennial herbaceous plant belonging to Araliaceae family. The natural habitat of ginseng includes northeastern China, Korea, and the highland regions of eastern Russia. The root is the primary part used for medicinal purposes, and its classification into raw, white, or red ginseng depends on the method of processing [161]. The three forms differ for chemical composition, potency and uses. Widely regarded as one of the most well-known herbal remedies, ginseng has been valued for its therapeutic properties since ancient times, initially in Chinese and Korean traditional medicine. Its prominence gradually extended to the West and continues today [161]. In folk medicine, ginseng root extracts have been used to treat a multitude of medical conditions such as hypodynamia, anorexia, shortness of breath, palpitation, insomnia, impotence, hemorrhage, general weakness, inflammatory states and diabetes [162,163]. A wide range of preclinical studies have demonstrated the therapeutic potential of ginseng and its bioactive constituents, emphasizing their anti-inflammatory, antioxidant, immunomodulatory, anti-fatigue, cardioprotective, and neuroprotective effects [164]. Ginsenosides, a group of triterpene saponins, have been recognized through phytochemical studies as the principal active ingredients in ginseng root extract [165]. Other notable constituents include polysaccharides, peptides, alkaloids, polyacetylenes, and phenolic compounds [165]. Clinical research corroborates the adaptogenic properties of ginseng extract, with documented effects including decreased exhaustion [166–168], improved stress resilience [169,170], enhanced mental performance during demanding tasks [170–173], and elevated mood [170,173]. The mechanism behind ginseng's adaptogenic effect is intricate and involves multiple interconnected pathways, including the reduction of oxidative stress and pro-inflammatory factors, the modulation of inflammasome components, the regulation of the hypothalamic-pituitary-adrenal (HPA) axis, the modulation of monoamine neurotransmission and neurotrophic factors expression [164,174].

Rhodiola rosea L. is a perennial herbaceous plant in the family Crassulaceae. Its natural distribution encompasses cold-climate and high-altitude regions of Europe, particularly Scandinavia, Siberia, and mountainous parts of Nord America and Asia. Traditionally, *R. rosea* root extract has been valued in Russian, Scandinavian, and Asian traditional medicine systems as a tonic to combat fatigue and sensation of weakness, improve physical performance, support mood, and help deal with stress and nervous system disorders [175–177]. Extensive preclinical studies have demonstrated that *R. rosea* and its constituents exhibit antioxidant, anti-inflammatory, cardioprotective, neuroprotective, anxiolytic, antidepressant and nootropic-like actions [176]. The observed pharmacological activities of *R. rosea* root extract are largely attributed to the presence of rosavins (phenylpropanoids) along with salidroside and tyrosol (both of which are phenylethanoid derivatives) [175,176]. Other classes of compounds present in *R. rosea* root extract are flavonoids, monoterpenes, triterpenes and phenolic acids [175,176]. In human clinical trials, *R. rosea* supplementation has been shown to reduce symptoms of physical and mental fatigue (especially under stress or demand) [178–180], enhance mental and physical performance [181,182], and improve mood disturbance [183–185]. The mechanisms behind the adaptogenic effects of *R. rosea* appear to be multifactorial, involving the modulation of the hypothalamic–pituitary–adrenal (HPA) axis (normalizing cortisol levels), the increase of monoamine levels in the brain (by blocking the enzyme monoamine oxidase), the stimulation of the expression and release of neuropeptide-Y and β -endorphins, the scavenging of reactive oxygen species, the upregulation of proteins protecting cells by stress-induced damages (e.g. heat shock proteins), and modulation of signaling pathways associated with cell survival, inflammation and stress resistance [176,177].

Withania somnifera (L.) Dunal, commonly known as ashwagandha, winter cherry or indian ginseng, is a perennial shrub belonging to the Solanaceae family. Native to the arid landscapes of India, the Middle East, and sections of Africa, it has since been cultivated globally owing to its

recognized healing potential [186]. The roots are the most used part for medicinal purposes, though leaves, berries, and seeds also possess bioactive compounds. Since ancient times, ashwagandha has held a prominent place in Ayurvedic medicine, where it is regarded as a Rasayana—a herbal remedy believed to enhance longevity, vitality, and resistance to stress. [187]. Its therapeutic applications in traditional medicine, alone or as ingredient in poly-herbal formulations, include treatment for fatigue, neurological disorders, infertility, inflammation, pain and general debility among the others [188]. A growing body of preclinical studies supports the pharmacological efficacy of ashwagandha, highlighting its anti-inflammatory, antioxidant, anxiolytic, immunomodulatory, neuroprotective, antitumoral and anti-fatigue properties [186,189,190]. Withanolides—steroidal lactones structurally similar to ginsenosides—are considered the primary active constituents of *W. somnifera* extract [191]. Additional bioactive compounds include alkaloids, sitoindosides, flavonoids, and saponins [190–193]. Ashwagandha’s adaptogenic efficacy is increasingly supported by clinical research, with reported benefits such as improved muscular strength and endurance [194–197], reduced stress-induced fatigue [198–200], better cognitive and executive functioning [201,202], lower perceived stress, and improved emotional well-being [203–205].

Mechanistically, ashwagandha extracts work in a complex and multi-target way to promote its adaptogenic effects, mainly through modulation of the hypothalamic-pituitary-adrenal (HPA) axis, attenuation of oxidative stress and neuroinflammation, and regulation of GABAergic neurotransmission [206].

5. References

- Salame, A.; Mathew, S.; Bhanu, C.; Bazo-Alvarez, J.C.; Bhamra, S.K.; Heinrich, M.; Walters, K.; Frost, R. Over-the-Counter Products for Insomnia in Adults: A Scoping Review of Randomised Controlled Trials. *Sleep Medicine* **2025**, *129*, 219–237, doi:10.1016/j.sleep.2025.02.027.
- Nandhini, S.; Narayanan, K.; Ilango, K. VALERIANA OFFICINALIS: A REVIEW OF ITS TRADITIONAL USES, PHYTOCHEMISTRY AND PHARMACOLOGY. *Asian Journal of Pharmaceutical and Clinical Research* **2018**, *11*, 36, doi:10.22159/ajpcr.2017.v11i1.22588.
- Patočka, J.; Jakl, J. Biomedically Relevant Chemical Constituents of *Valeriana Officinalis*. *Journal of Applied Biomedicine* **2010**, *8*, 11–18, doi:10.2478/v10136-009-0002-z.
- Khom, S.; Baburin, I.; Timin, E.; Hohaus, A.; Trauner, G.; Kopp, B.; Hering, S. Valerenic Acid Potentiates and Inhibits GABAA Receptors: Molecular Mechanism and Subunit Specificity. *Neuropharmacology* **2007**, *53*, 178–187, doi:10.1016/j.neuropharm.2007.04.018.
- Mulyawan, E.; Ahmad, M.; Islam, A.; Massi, M.; Hatta, M.; Arif, S. Analysis of GABRB3 Protein Level After Administration of Valerian Extract (*Valeriana Officinalis*) in BALB/c Mice. *Pharmacognosy Journal* **2020**, *12*, 821–827, doi:10.5530/pj.2020.12.118.
- Shinjyo, N.; Waddell, G.; Green, J. Valerian Root in Treating Sleep Problems and Associated Disorders—A Systematic Review and Meta-Analysis. *J Evid Based Integr Med* **2020**, *25*, 2515690X20967323, doi:10.1177/2515690X20967323.
- Ghasemzadeh Rahbardar, M.; Hosseinzadeh, H. Therapeutic Potential of Hypnotic Herbal Medicines: A Comprehensive Review. *Phytother Res* **2024**, *38*, 3037–3059, doi:10.1002/ptr.8201.
- Dorn, M. [Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative study]. *Forsch Komplementarmed Klass Naturheilkd* **2000**, *7*, 79–84, doi:10.1159/000021314.

9. Ziegler, G.; Ploch, M.; Miettinen-Baumann, A.; Collet, W. Efficacy and Tolerability of Valerian Extract LI 156 Compared with Oxazepam in the Treatment of Non-Organic Insomnia--a Randomized, Double-Blind, Comparative Clinical Study. *Eur J Med Res* **2002**, *7*, 480–486. 413
414
415
10. Koetter, U.; Schrader, E.; Käufeler, R.; Brattström, A. A Randomized, Double Blind, Placebo-Controlled, Prospective Clinical Study to Demonstrate Clinical Efficacy of a Fixed Valerian Hops Extract Combination (Ze 91019) in Patients Suffering from Non-Organic Sleep Disorder. *Phytotherapy Research* **2007**, *21*, 847–851, doi:10.1002/ptr.2167. 416
417
418
11. Schickanz, N.; Gerhards, C.; Schlitt, T.; Aerni, A.; Müggler, E.; de Quervain, D.; Papassotiropoulos, A.; Boonen, G.; Drewe, J.; Butterweck, V. Effects of a Valerian-Hops Extract Combination (Ze 91019) on Sleep Duration and Daytime Cognitive and Psychological Parameters in Occasional Insomnia: A Randomized Controlled Feasibility Trial. *Brain Behav* **2025**, *15*, e70600, doi:10.1002/brb3.70600. 419
420
421
422
12. Maroo, N.; Hazra, A.; Das, T. Efficacy and Safety of a Polyherbal Sedative-Hypnotic Formulation NSF-3 in Primary Insomnia in Comparison to Zolpidem: A Randomized Controlled Trial. *Indian J Pharmacol* **2013**, *45*, 34–39, doi:10.4103/0253-7613.106432. 423
424
425
13. Bej, E.; Volpe, A.R.; Cesare, P.; Cimini, A.; d'Angelo, M.; Castelli, V. Therapeutic Potential of Saffron in Brain Disorders: From Bench to Bedside. *Phytother Res* **2024**, *38*, 2482–2495, doi:10.1002/ptr.8169. 426
427
14. Alavizadeh, S.H.; Hosseinzadeh, H. Bioactivity Assessment and Toxicity of Crocin: A Comprehensive Review. *Food and Chemical Toxicology* **2014**, *64*, 65–80, doi:10.1016/j.fct.2013.11.016. 428
429
15. Ghasemzadeh Rahbardar, M.; Hosseinzadeh, H. A Review of How the Saffron (*Crocus Sativus*) Petal and Its Main Constituents Interact with the Nrf2 and NF- κ B Signaling Pathways. *Naunyn-Schmiedeberg's Arch Pharmacol* **2023**, *396*, 1879–1909, doi:10.1007/s00210-023-02487-5. 430
431
432
16. Siddiqui, S.A.; Ali Redha, A.; Snoeck, E.R.; Singh, S.; Simal-Gandara, J.; Ibrahim, S.A.; Jafari, S.M. Anti-Depressant Properties of Crocin Molecules in Saffron. *Molecules* **2022**, *27*, 2076, doi:10.3390/molecules27072076. 433
434
17. Lian, J.; Zhong, Y.; Li, H.; Yang, S.; Wang, J.; Li, X.; Zhou, X.; Chen, G. Effects of Saffron Supplementation on Improving Sleep Quality: A Meta-Analysis of Randomized Controlled Trials. *Sleep Medicine* **2022**, *92*, 24–33, doi:10.1016/j.sleep.2022.03.001. 435
436
437
18. Munirah, M.P.; Norhayati, M.N.; Noraini, M. *Crocus Sativus* for Insomnia: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* **2022**, *19*, 11658, doi:10.3390/ijerph191811658. 438
439
19. Han, S.; Cao, Y.; Wu, X.; Xu, J.; Nie, Z.; Qiu, Y. New Horizons for the Study of Saffron (*Crocus Sativus* L.) and Its Active Ingredients in the Management of Neurological and Psychiatric Disorders: A Systematic Review of Clinical Evidence and Mechanisms. *Phytotherapy Research* **2024**, *38*, 2276–2302, doi:10.1002/ptr.8110. 440
441
442
20. Hosseinzadeh, H.; Sadeghnia, H.R. Protective Effect of Safranal on Pentylentetrazol-Induced Seizures in the Rat: Involvement of GABAergic and Opioids Systems. *Phytomedicine* **2007**, *14*, 256–262, doi:10.1016/j.phymed.2006.03.007. 443
444
21. de Melo Alves Silva, L.C.; de Oliveira Mendes, F. de C.; de Castro Teixeira, F.; de Lima Fernandes, T.E.; Barros Ribeiro, K.R.; da Silva Leal, K.C.; Dantas, D.V.; Neves Dantas, R.A. Use of *Lavandula Angustifolia* Essential Oil as a Complementary Therapy in Adult Health Care: A Scoping Review. *Heliyon* **2023**, *9*, e15446, doi:10.1016/j.heliyon.2023.e15446. 445
446
447
448
22. Dobros, N.; Zawada, K.D.; Paradowska, K. Phytochemical Profiling, Antioxidant and Anti-Inflammatory Activity of Plants Belonging to the *Lavandula* Genus. *Molecules* **2022**, *28*, 256, doi:10.3390/molecules28010256. 449
450
23. Vora, L.K.; Gholap, A.D.; Hatvate, N.T.; Naren, P.; Khan, S.; Chavda, V.P.; Balar, P.C.; Gandhi, J.; Khatri, D.K. Essential Oils for Clinical Aromatherapy: A Comprehensive Review. *J Ethnopharmacol* **2024**, *330*, 118180, doi:10.1016/j.jep.2024.118180. 451
452
453
24. Caballero-Gallardo, K.; Quintero-Rincón, P.; Olivero-Verbel, J. Aromatherapy and Essential Oils: Holistic Strategies in Complementary and Alternative Medicine for Integral Wellbeing. *Plants (Basel)* **2025**, *14*, 400, doi:10.3390/plants14030400. 454
455
456

25. Soares, G.A.B. e; Bhattacharya, T.; Chakrabarti, T.; Tagde, P.; Cavalu, S. Exploring Pharmacological Mechanisms of Essential Oils on the Central Nervous System. *Plants (Basel)* **2021**, *11*, 21, doi:10.3390/plants11010021. 457
458
26. Cheong, M.J.; Kim, S.; Kim, J.S.; Lee, H.; Lyu, Y.-S.; Lee, Y.R.; Jeon, B.; Kang, H.W. A Systematic Literature Review and Meta-Analysis of the Clinical Effects of Aroma Inhalation Therapy on Sleep Problems. *Medicine (Baltimore)* **2021**, *100*, e24652, doi:10.1097/MD.00000000000024652. 459
460
461
27. Cheng, H.; Lin, L.; Wang, S.; Zhang, Y.; Liu, T.; Yuan, Y.; Chen, Q.; Tian, L. Aromatherapy with Single Essential Oils Can Significantly Improve the Sleep Quality of Cancer Patients: A Meta-Analysis. *BMC Complement Med Ther* **2022**, *22*, 187, doi:10.1186/s12906-022-03668-0. 462
463
464
28. Xu, K.; Wang, S.; Ji, Q.; Ni, Y.; Liu, T. Effects of Aromatherapy on Sleep Quality in Older Adults: A Meta-Analysis. *Medicine (Baltimore)* **2024**, *103*, e40688, doi:10.1097/MD.00000000000040688. 465
466
29. Sivamaruthi, B.S.; Kesika, P.; Sisubalan, N.; Chaiyasut, C. The Role of Essential Oils on Sleep Quality and Other Sleep-Related Issues: Evidence from Clinical Trials. *Mini Rev Med Chem* **2025**, *25*, 234–258, doi:10.2174/0113895575315700240821054716. 467
468
469
30. Woelk, H.; Schläfke, S. A Multi-Center, Double-Blind, Randomised Study of the Lavender Oil Preparation Silexan in Comparison to Lorazepam for Generalized Anxiety Disorder. *Phytomedicine* **2010**, *17*, 94–99, doi:10.1016/j.phymed.2009.10.006. 470
471
472
31. Kasper, S.; Gastpar, M.; Müller, W.E.; Volz, H.-P.; Möller, H.-J.; Dienel, A.; Schläfke, S. Silexan, an Orally Administered Lavandula Oil Preparation, Is Effective in the Treatment of “subsyndromal” Anxiety Disorder: A Randomized, Double-Blind, Placebo Controlled Trial. *Int Clin Psychopharmacol* **2010**, *25*, 277–287, doi:10.1097/YIC.0b013e32833b3242. 473
474
475
476
32. Möller, H.-J.; Volz, H.-P.; Dienel, A.; Schläfke, S.; Kasper, S. Efficacy of Silexan in Subthreshold Anxiety: Meta-Analysis of Randomised, Placebo-Controlled Trials. *Eur Arch Psychiatry Clin Neurosci* **2019**, *269*, 183–193, doi:10.1007/s00406-017-0852-4. 477
478
479
33. Seifritz, E.; Kasper, S.; Möller, H.-J.; Volz, H.-P.; Müller, W.E.; Eckert, A.; Hatzinger, M. Effect of Anxiolytic Drug Silexan on Sleep – a Narrative Review. *The World Journal of Biological Psychiatry* **2022**, *23*, 493–500, doi:10.1080/15622975.2021.2013092. 480
481
482
34. Huang, L.; Abuhamdah, S.; Howes, M.-J.R.; Dixon, C.L.; Elliot, M.S.J.; Ballard, C.; Holmes, C.; Burns, A.; Perry, E.K.; Francis, P.T.; et al. Pharmacological Profile of Essential Oils Derived from Lavandula Angustifolia and Melissa Officinalis with Anti-Agitation Properties: Focus on Ligand-Gated Channels. *J Pharm Pharmacol* **2008**, *60*, 1515–1522, doi:10.1211/jpp/60.11.0013. 483
484
485
486
35. Chioca, L.R.; Ferro, M.M.; Baretta, I.P.; Oliveira, S.M.; Silva, C.R.; Ferreira, J.; Losso, E.M.; Andreatini, R. Anxiolytic-like Effect of Lavender Essential Oil Inhalation in Mice: Participation of Serotonergic but Not GABAA/Benzodiazepine Neurotransmission. *Journal of Ethnopharmacology* **2013**, *147*, 412–418, doi:10.1016/j.jep.2013.03.028. 487
488
489
490
36. Schuwald, A.M.; Nöldner, M.; Wilmes, T.; Klugbauer, N.; Leuner, K.; Müller, W.E. Lavender Oil-Potent Anxiolytic Properties via Modulating Voltage Dependent Calcium Channels. *PLoS One* **2013**, *8*, e59998, doi:10.1371/journal.pone.0059998. 491
492
493
37. Awlqadr, F.H.; Altemimi, A.B.; Qadir, S.A.; Mohammed, O.A.; Saeed, M.N.; Hesarinejad, M.A.; Lakhssassi, N. Bioactive Compounds, Medicinal Benefits, and Contemporary Extraction Methods for Lemon Balm (*Melissa Officinalis*). *Food Science & Nutrition* **2025**, *13*, e70864, doi:10.1002/fsn3.70864. 494
495
496
38. Draginic, N.; Andjic, M.; Jeremic, J.; Zivkovic, V.; Kocovic, A.; Tomovic, M.; Bozin, B.; Kladar, N.; Bolevich, S.; Jakovljevic, V.; et al. Anti-Inflammatory and Antioxidant Effects of *Melissa Officinalis* Extracts: A Comparative Study. *Iran J Pharm Res* **2022**, *21*, e126561, doi:10.5812/ijpr-126561. 497
498
499

39. Petrisor, G.; Motelica, L.; Craciun, L.N.; Oprea, O.C.; Fikai, D.; Fikai, A. Melissa Officinalis: Composition, Pharmacological Effects and Derived Release Systems—A Review. *Int J Mol Sci* **2022**, *23*, 3591, doi:10.3390/ijms23073591. 500
40. Cases, J.; Ibarra, A.; Feuillère, N.; Roller, M.; Sukkar, S.G. Pilot Trial of Melissa Officinalis L. Leaf Extract in the Treatment of Volunteers Suffering from Mild-to-Moderate Anxiety Disorders and Sleep Disturbances. *Med J Nutrition Metab* **2011**, *4*, 211–218, doi:10.1007/s12349-010-0045-4. 501
41. Aliakbari, F. The Effectiveness of Melissa Officinalis on Sleep Problem in Patients with Chronic Heart Failure. *Journal of Pharmaceutical Negative Results* **2018**, *9*, 55–58. 502
42. Haybar, H.; Javid, A.Z.; Haghighizadeh, M.H.; Valizadeh, E.; Mohaghegh, S.M.; Mohammadzadeh, A. The Effects of Melissa Officinalis Supplementation on Depression, Anxiety, Stress, and Sleep Disorder in Patients with Chronic Stable Angina. *Clinical Nutrition ESPEN* **2018**, *26*, 47–52, doi:10.1016/j.clnesp.2018.04.015. 503
43. Heydari, N.; Deghani, M.; Emamghoreishi, M.; Akbarzadeh, M. Effect of Melissa Officinalis Capsule on the Mental Health of Female Adolescents with Premenstrual Syndrome: A Clinical Trial Study. *International Journal of Adolescent Medicine and Health* **2019**, *31*, doi:10.1515/ijamh-2017-0015. 504
44. Soltanpour, A.; Alijaniha, F.; Naseri, M.; Kazemnejad, A.; Heidari, M.R. Effects of *Melissa Officinalis* on Anxiety and Sleep Quality in Patients Undergoing Coronary Artery Bypass Surgery: A Double-Blind Randomized Placebo Controlled Trial. *European Journal of Integrative Medicine* **2019**, *28*, 27–32, doi:10.1016/j.eujim.2019.01.010. 505
45. Safari, M.; Asadi, A.; Aryaeian, N.; Huseini, H.F.; shidfar, F.; Jazayeri, S.; Malek, M.; Hosseini, A.F.; hamidi, Z. The Effects of Melissa Officinalis on Depression and Anxiety in Type 2 Diabetes Patients with Depression: A Randomized Double-Blinded Placebo-Controlled Clinical Trial. *BMC Complement Med Ther* **2023**, *23*, 140, doi:10.1186/s12906-023-03978-x. 506
46. Shirazi, M.; Jalalian, M.N.; Abed, M.; Ghaemi, M. The Effectiveness of Melissa Officinalis L. versus Citalopram on Quality of Life of Menopausal Women with Sleep Disorder: A Randomized Double-Blind Clinical Trial. *Rev Bras Ginecol Obstet* **2021**, *43*, 126–130, doi:10.1055/s-0040-1721857. 507
47. Di Pierro, F.; Sisti, D.; Rocchi, M.; Belli, A.; Bertuccioli, A.; Cazzaniga, M.; Palazzi, C.M.; Tanda, M.L.; Zerbinati, N. Effects of Melissa Officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study. *Nutrients* **2024**, *16*, 4199, doi:10.3390/nu16234199. 508
48. Wang, C.-C.; Hsieh, P.-W.; Kuo, J.-R.; Wang, S.-J. Rosmarinic Acid, a Bioactive Phenolic Compound, Inhibits Glutamate Release from Rat Cerebrocortical Synaptosomes through GABAA Receptor Activation. *Biomolecules* **2021**, *11*, 1029, doi:10.3390/biom11071029. 509
49. Awad, R.; Muhammad, A.; Durst, T.; Trudeau, V.L.; Arnason, J.T. Bioassay-Guided Fractionation of Lemon Balm (*Melissa Officinalis* L.) Using an in Vitro Measure of GABA Transaminase Activity. *Phytotherapy Research* **2009**, *23*, 1075–1081, doi:10.1002/ptr.2712. 510
50. Mandal, S.K.; Rath, S.K.; Logesh, R.; Mishra, S.K.; Devkota, H.P.; Das, N. Capsicum Annuum L. and Its Bioactive Constituents: A Critical Review of a Traditional Culinary Spice in Terms of Its Modern Pharmacological Potentials with Toxicological Issues. *Phytotherapy Research* **2023**, *37*, 965–1002, doi:10.1002/ptr.7660. 511
51. Keitel, W.; Frerick, H.; Kuhn, U.; Schmidt, U.; Kuhlmann, M.; Bredehorst, A. Capsicum Pain Plaster in Chronic Non-Specific Low Back Pain. *Arzneimittelforschung* **2001**, *51*, 896–903, doi:10.1055/s-0031-1300134. 512
52. Frerick, H.; Keitel, W.; Kuhn, U.; Schmidt, S.; Bredehorst, A.; Kuhlmann, M. Topical Treatment of Chronic Low Back Pain with a Capsicum Plaster. *Pain* **2003**, *106*, 59–64, doi:10.1016/s0304-3959(03)00278-1. 513
53. Chrubasik, S.; Weiser, T.; Beime, B. Effectiveness and safety of topical capsaicin cream in the treatment of chronic soft tissue pain. *Phytotherapy Research* **2010**, *24*, 1877–1885, doi:10.1002/ptr.3335. 514
54. Kim, K.S.; Kim, D.W.; Yu, Y.K. The Effect of Capsicum Plaster in Pain after Inguinal Hernia Repair in Children. *Pediatric Anesthesia* **2006**, *16*, 1036–1041, doi:10.1111/j.1460-9592.2006.01927.x. 515

55. Kim, K.S.; Nam, Y.M. The Analgesic Effects of Capsicum Plaster at the Zusanli Point after Abdominal Hysterectomy. *Anesth Analg* **2006**, *103*, 709–713, doi:10.1213/01.ane.0000228864.74691.9f. 543
56. Kim, K.S.; Kim, K.N.; Hwang, K.G.; Park, C.J. Capsicum Plaster at the Hegu Point Reduces Postoperative Analgesic Requirement after Orthognathic Surgery. *Anesth Analg* **2009**, *108*, 992–996, doi:10.1213/ane.0b013e318195b78f. 544
57. van Nooten, F.; Treur, M.; Pantiri, K.; Stoker, M.; Charokopou, M. Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-Analysis. *Clinical Therapeutics* **2017**, *39*, 787–803.e18, doi:10.1016/j.clinthera.2017.02.010. 545
58. Jahromi, B.; Pirvulescu, I.; Candido, K.D.; Knezevic, N.N. Herbal Medicine for Pain Management: Efficacy and Drug Interactions. *Pharmaceutics* **2021**, *13*, 251, doi:10.3390/pharmaceutics13020251. 546
59. Tshering, G.; Posadzki, P.; Kongkaew, C. Efficacy and Safety of Topical Capsaicin in the Treatment of Osteoarthritis Pain: A Systematic Review and Meta-Analysis. *Phytotherapy Research* **2024**, *38*, 3695–3705, doi:10.1002/ptr.8223. 547
60. Pepelyayeva, Y.; Rardin, B.; Simpson, D.; Leavell, Y. Chapter 8 - High-Dose Capsaicin Patch for Pain Relief: Clinical Experience. In *TRP Channels as Therapeutic Targets (Second Edition)*; Szallasi, A., Ed.; Academic Press, 2024; pp. 115–141 ISBN 978-0-443-18653-0. 548
61. Chung, M.-K.; Campbell, J.N. Use of Capsaicin to Treat Pain: Mechanistic and Therapeutic Considerations. *Pharmaceutics* **2016**, *9*, 66, doi:10.3390/ph9040066. 549
62. Tian, W.-W.; Liu, L.; Chen, P.; Yu, D.-M.; Li, Q.-M.; Hua, H.; Zhao, J.-N. Curcuma Longa (Turmeric): From Traditional Applications to Modern Plant Medicine Research Hotspots. *Chin Med* **2025**, *20*, 76, doi:10.1186/s13020-025-01115-z. 550
63. Zhang, P.; Liu, H.; Yu, Y.; Peng, S.; Zhu, S. Role of Curcuma Longae Rhizoma in Medical Applications: Research Challenges and Opportunities. *Front Pharmacol* **2024**, *15*, 1430284, doi:10.3389/fphar.2024.1430284. 551
64. Zhang, H.A.; Kitts, D.D. Turmeric and Its Bioactive Constituents Trigger Cell Signaling Mechanisms That Protect against Diabetes and Cardiovascular Diseases. *Mol Cell Biochem* **2021**, *476*, 3785–3814, doi:10.1007/s11010-021-04201-6. 552
65. Hajimirzaei, P.; Eyni, H.; Razmgir, M.; Abolfazli, S.; Pirzadeh, S.; Ahmadi Tabatabaei, F.S.; Vasigh, A.; Yazdanian, N.; Ramezani, F.; Janzadeh, A.; et al. The Analgesic Effect of Curcumin and Nano-Curcumin in Clinical and Preclinical Studies: A Systematic Review and Meta-Analysis. *Naunyn-Schmiedeberg's Arch Pharmacol* **2025**, *398*, 393–416, doi:10.1007/s00210-024-03369-0. 553
66. Zhao, J.; Liang, G.; Zhou, G.; Hong, K.; Yang, W.; Liu, J.; Zeng, L. Efficacy and Safety of Curcumin Therapy for Knee Osteoarthritis: A Bayesian Network Meta-Analysis. *Journal of Ethnopharmacology* **2024**, *321*, 117493, doi:10.1016/j.jep.2023.117493. 554
67. Wai, H.S.; Pathomwachaiwat, T.; Suansanae, T.; Nathisuwan, S.; Rattanavipanon, W. Effect of Turmeric Products on Knee Osteoarthritis: A Systematic Review and Network Meta-Analysis. *BMC Complement Med Ther* **2025**, *25*, 292, doi:10.1186/s12906-025-05045-z. 555
68. Pinsornsak, P.; Niempoog, S. The Efficacy of Curcuma Longa L. Extract as an Adjuvant Therapy in Primary Knee Osteoarthritis: A Randomized Control Trial. *J Med Assoc Thai* **2012**, *95 Suppl 1*, S51-58. 556
69. Srivastava, S.; Saksena, A.K.; Khattri, S.; Kumar, S.; Dagur, R.S. Curcuma Longa Extract Reduces Inflammatory and Oxidative Stress Biomarkers in Osteoarthritis of Knee: A Four-Month, Double-Blind, Randomized, Placebo-Controlled Trial. *Inflammopharmacology* **2016**, *24*, 377–388, doi:10.1007/s10787-016-0289-9. 557
70. Atabaki, Mahdi.; Shariati-Sarabi, Zhaleh.; Tavakkol-Afshari, Jalil.; Mohammadi, Mojgan. Significant Immunomodulatory Properties of Curcumin in Patients with Osteoarthritis; a Successful Clinical Trial in Iran. *International Immunopharmacology* **2020**, *85*, 106607, doi:10.1016/j.intimp.2020.106607. 558

71. Shep, D.; Khanwelkar, C.; Gade, P.; Karad, S. Efficacy and Safety of Combination of Curcuminoid Complex and Diclofenac versus Diclofenac in Knee Osteoarthritis. *Medicine (Baltimore)* **2020**, *99*, e19723, doi:10.1097/MD.00000000000019723. 585
586
587
72. Gupta, A.; Agarwal, A. The Effect of Turmeric-Boswellia Formulation (Rhuleave-K) in Posture-Related Low Back Soreness and Discomfort: A Randomized Double Blinded Placebo Controlled Trial. *Journal of Back and Musculoskeletal Rehabilitation* **2025**, *38*, 494–505, doi:10.1177/10538127241296343. 588
589
590
73. Majumdar, A.; Prasad, M.A.V.V.; Gandavarapu, S.R.; Reddy, K.S.K.; Sureja, V.; Kheni, D.; Dubey, V. Efficacy and Safety Evaluation of *Boswellia Serrata* and *Curcuma Longa* Extract Combination in the Management of Chronic Lower Back Pain: A Randomised, Double-Blind, Placebo-Controlled Clinical Study. *EXPLORE* **2025**, *21*, 103099, doi:10.1016/j.explore.2024.103099. 591
592
593
594
74. Rudrappa, G.H.; Murthy, M.; Saklecha, S.; Kumar Kare, S.; Gupta, A.; Basu, I. Fast Pain Relief in Exercise-Induced Acute Musculoskeletal Pain by Turmeric-Boswellia Formulation: A Randomized Placebo-Controlled Double-Blinded Multicentre Study. *Medicine (Baltimore)* **2022**, *101*, e30144, doi:10.1097/MD.00000000000030144. 595
596
597
75. Bengmark, S. Curcumin, An Atoxic Antioxidant and Natural NFκB, Cyclooxygenase-2, Lipooxygenase, and Inducible Nitric Oxide Synthase Inhibitor: A Shield Against Acute and Chronic Diseases. *Journal of Parenteral and Enteral Nutrition* **2006**, *30*, 45–51, doi:10.1177/014860710603000145. 598
599
600
76. Jurenka, J.S. Anti-Inflammatory Properties of Curcumin, a Major Constituent of *Curcuma Longa*: A Review of Preclinical and Clinical Research. *Altern Med Rev* **2009**, *14*, 141–153. 601
602
77. Hasriadi; Dasuni Wasana, P.W.; Vajragupta, O.; Rojsitthisak, P.; Towiwat, P. Mechanistic Insight into the Effects of Curcumin on Neuroinflammation-Driven Chronic Pain. *Pharmaceuticals (Basel)* **2021**, *14*, 777, doi:10.3390/ph14080777. 603
604
78. Daimei, P.; Kumar, Y. Ethnobotanical Uses of Gingers in Tamenglong District, Manipur, Northeast India. *Genet Resour Crop Evol* **2014**, *61*, 273–285, doi:10.1007/s10722-013-0054-5. 605
606
79. Shahrajabian, M.H.; Sun, W.; Cheng, Q. Clinical Aspects and Health Benefits of Ginger (*Zingiber Officinale*) in Both Traditional Chinese Medicine and Modern Industry. *Acta Agriculturae Scandinavica, Section B – Soil & Plant Science* **2019**, *69*, 546–556, doi:10.1080/09064710.2019.1606930. 607
608
609
80. Inta, A.; Trisonthi, C.; Pongamornkul, W.; Panyadee, P. Ethnobotany of Zingiberaceae in Mae Hong Son, Northern Thailand. *Biodiversitas Journal of Biological Diversity* **2023**, *24*, doi:10.13057/biodiv/d240422. 610
611
81. Verma, P.K.; Singh, B.; Sharma, P.; Tukra, S.; Ait-Kaddour, A.; Bhat, Z.F. Mechanistic Advances and Therapeutic Applications of *Zingiber Officinale* Roscoe. *Food Chemistry Advances* **2025**, *8*, 101060, doi:10.1016/j.focha.2025.101060. 612
613
82. Mao, Q.-Q.; Xu, X.-Y.; Cao, S.-Y.; Gan, R.-Y.; Corke, H.; Beta, T.; Li, H.-B. Bioactive Compounds and Bioactivities of Ginger (*Zingiber Officinale* Roscoe). *Foods* **2019**, *8*, 185, doi:10.3390/foods8060185. 614
615
83. Mathieu, S.; Soubrier, M.; Peirs, C.; Monfoulet, L.-E.; Boirie, Y.; Tournadre, A. A Meta-Analysis of the Impact of Nutritional Supplementation on Osteoarthritis Symptoms. *Nutrients* **2022**, *14*, 1607, doi:10.3390/nu14081607. 616
617
84. Moshfeghinia, R.; Salmanpour, N.; Ghoshouni, H.; Gharedaghi, H.; Zare, R.; Cramer, H.; Heydarirad, G.; Pasalar, M. Ginger for Pain Management in Primary Dysmenorrhea: A Systematic Review and Meta-Analysis. *Journal of Integrative and Complementary Medicine* **2024**, *30*, 1016–1030, doi:10.1089/jicm.2023.0799. 618
619
620
85. Chen, L.; Cai, Z. The Efficacy of Ginger for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies. *The American Journal of Emergency Medicine* **2021**, *46*, 567–571, doi:10.1016/j.ajem.2020.11.030. 621
622
86. Broeckel, J.; Estes, L.; Leonard, M.; Dickerson, B.L.; Gonzalez, D.E.; Purpura, M.; Jäger, R.; Sowinski, R.J.; Rasmussen, C.J.; Kreider, R.B. Effects of Ginger Supplementation on Markers of Inflammation and Functional Capacity in Individuals with Mild to Moderate Joint Pain. *Nutrients* **2025**, *17*, 2365, doi:10.3390/nu17142365. 623
624
625
87. Wilson, P.B. A Randomized Double-Blind Trial of Ginger Root for Reducing Muscle Soreness and Improving Physical Performance Recovery Among Experienced Recreational Distance Runners. *J Diet Suppl* **2020**, *17*, 121–132, doi:10.1080/19390211.2018.1492484. 626
627
628

88. Rondanelli, M.; Fossari, F.; Vecchio, V.; Gasparri, C.; Peroni, G.; Spadaccini, D.; Riva, A.; Petrangolini, G.; Iannello, G.; Nichetti, M.; et al. Clinical Trials on Pain Lowering Effect of Ginger: A Narrative Review. *Phytother Res* **2020**, *34*, 2843–2856, doi:10.1002/ptr.6730. 629–631
89. Kim, S.; Cheon, C.; Kim, B.; Kim, W. The Effect of Ginger and Its Sub-Components on Pain. *Plants (Basel)* **2022**, *11*, 2296, doi:10.3390/plants11172296. 632–633
90. Montinari, M.R.; Minelli, S.; De Caterina, R. The First 3500 years of Aspirin History from Its Roots - A Concise Summary. *Vascul Pharmacol* **2019**, *113*, 1–8, doi:10.1016/j.vph.2018.10.008. 634–635
91. Fontana, F. La Salicina, Principio Medicamentoso Del Salice Bianco (*Salix Alba*) o Base Vegetale Salificabile. *Giornale di Farmacia-Chimica e Scienze Accessorie o sia Raccolta delle scoperte, ritrovati e miglioramenti fatti in Farmacia ed in Chimica* **1**, 644–648. 636–638
92. Rigatelli, B. Sostituto Indigeno Del Solfato Di Chinina. *Biblioteca Italiana o sia Giornale di Letteratura, Scienze ed Arti* **1824**, *33*, 267–271. 639–640
93. Tawfeek, N.; Mahmoud, M.F.; Hamdan, D.I.; Sobeh, M.; Farrag, N.; Wink, M.; El-Shazly, A.M. Phytochemistry, Pharmacology and Medicinal Uses of Plants of the Genus *Salix*: An Updated Review. *Front Pharmacol* **2021**, *12*, 593856, doi:10.3389/fphar.2021.593856. 641–643
94. Oketch-Rabah, H.A.; Marles, R.J.; Jordan, S.A.; Low Dog, T. United States Pharmacopeia Safety Review of Willow Bark. *Planta Med* **2019**, *85*, 1192–1202, doi:10.1055/a-1007-5206. 644–645
95. Vlachojannis, J.; Magora, F.; Chrubasik, S. Willow Species and Aspirin: Different Mechanism of Actions. *Phytother Res* **2011**, *25*, 1102–1104, doi:10.1002/ptr.3386. 646–647
96. Chrubasik, S.; Eisenberg, E.; Balan, E.; Weinberger, T.; Luzzati, R.; Conradt, C. Treatment of Low Back Pain Exacerbations with Willow Bark Extract: A Randomized Double-Blind Study. *The American Journal of Medicine* **2000**, *109*, 9–14, doi:10.1016/S0002-9343(00)00442-3. 648–650
97. Chrubasik, S.; Künzel, O.; Black, A.; Conradt, C.; Kerschbaumer, F. Potential Economic Impact of Using a Proprietary Willow Bark Extract in Outpatient Treatment of Low Back Pain: An Open Non-Randomized Study. *Phytomedicine* **2001**, *8*, 241–251, doi:10.1078/0944-7113-00048. 651–653
98. Chrubasik, S.; Künzel, O.; Model, A.; Conradt, C.; Black, A. Treatment of Low Back Pain with a Herbal or Synthetic Anti-rheumatic: A Randomized Controlled Study. Willow Bark Extract for Low Back Pain. *Rheumatology (Oxford)* **2001**, *40*, 1388–1393, doi:10.1093/rheumatology/40.12.1388. 654–656
99. Uehleke, B.; Müller, J.; Stange, R.; Kelber, O.; Melzer, J. Willow Bark Extract STW 33-I in the Long-Term Treatment of Outpatients with Rheumatic Pain Mainly Osteoarthritis or Back Pain. *Phytomedicine* **2013**, *20*, 980–984, doi:10.1016/j.phymed.2013.03.023. 657–659
100. Brendler, T. From Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil's Claw (*Harpagophytum Spp.*). *Pharmaceuticals (Basel)* **2021**, *14*, 726, doi:10.3390/ph14080726. 660–661
101. Mncwangi, N.; Chen, W.; Vermaak, I.; Viljoen, A.M.; Gericke, N. Devil's Claw—A Review of the Ethnobotany, Phytochemistry and Biological Activity of *Harpagophytum Procumbens*. *Journal of Ethnopharmacology* **2012**, *143*, 755–771, doi:10.1016/j.jep.2012.08.013. 662–664
102. Gxaba, N.; Manganyi, M.C. The Fight against Infection and Pain: Devil's Claw (*Harpagophytum Procumbens*) a Rich Source of Anti-Inflammatory Activity: 2011–2022. *Molecules* **2022**, *27*, 3637, doi:10.3390/molecules27113637. 665–666
103. Oltean, H.; Robbins, C.; van Tulder, M.W.; Berman, B.M.; Bombardier, C.; Gagnier, J.J. Herbal Medicine for Low-back Pain. *Cochrane Database Syst Rev* **2014**, *2014*, CD004504, doi:10.1002/14651858.CD004504.pub4. 667–668
104. Maouche, A.; Boumediene, K.; Baugé, C. Bioactive Compounds in Osteoarthritis: Molecular Mechanisms and Therapeutic Roles. *Int J Mol Sci* **2024**, *25*, 11656, doi:10.3390/ijms252111656. 669–670

105. Chantre, P.; Cappelaere, A.; Leblan, D.; Guedon, D.; Vandermander, J.; Fournie, B. Efficacy and Tolerance of *Harpagophytum Procumbens* versus Diacerhein in Treatment of Osteoarthritis. *Phytomedicine* **2000**, *7*, 177–183, doi:10.1016/S0944-7113(00)80001-X. 671
672
673
106. Leblan, D.; Chantre, P.; Fournié, B. Harpagophytum Procumbens in the Treatment of Knee and Hip Osteoarthritis. Four-Month Results of a Prospective, Multicenter, Double-Blind Trial versus Diacerhein. *Joint Bone Spine* **2000**, *67*, 462–467. 674
675
676
107. Chrubasik, S.; Model, A.; Black, A.; Pollak, S. A Randomized Double-blind Pilot Study Comparing Doloteffin® and Vioxx® in the Treatment of Low Back Pain. *Rheumatology (Oxford)* **2003**, *42*, 141–148, doi:10.1093/rheumatology/keg053. 677
678
679
108. Mariano, A.; Di Sotto, A.; Leopizzi, M.; Garzoli, S.; Di Maio, V.; Gulli, M.; Dalla Vedova, P.; Ammendola, S.; Scotto d’Abusco, A. Antiarthritic Effects of a Root Extract from Harpagophytum Procumbens DC: Novel Insights into the Molecular Mechanisms and Possible Bioactive Phytochemicals. *Nutrients* **2020**, *12*, 2545, doi:10.3390/nu12092545. 680
681
682
109. Bongers, F.; Groenendijk, P.; Bekele, T.; Birhane, E.; Damtew, A.; Decuyper, M.; Eshete, A.; Gezahgne, A.; Girma, A.; Khamis, M.A.; et al. Frankincense in Peril. *Nat Sustain* **2019**, *2*, 602–610, doi:10.1038/s41893-019-0322-2. 683
684
110. Moussaieff, A.; Mechoulam, R. Boswellia Resin: From Religious Ceremonies to Medical Uses; a Review of in-Vitro, in-Vivo and Clinical Trials. *Journal of Pharmacy and Pharmacology* **2009**, *61*, 1281–1293, doi:10.1211/jpp.61.10.0003. 685
686
111. Iram, F.; Khan, S.A.; Husain, A. Phytochemistry and Potential Therapeutic Actions of Boswellic Acids: A Mini-Review. *Asian Pacific Journal of Tropical Biomedicine* **2017**, *7*, 513–523, doi:10.1016/j.apjtb.2017.05.001. 687
688
112. Yu, G.; Xiang, W.; Zhang, T.; Zeng, L.; Yang, K.; Li, J. Effectiveness of Boswellia and Boswellia Extract for Osteoarthritis Patients: A Systematic Review and Meta-Analysis. *BMC Complement Med Ther* **2020**, *20*, 225, doi:10.1186/s12906-020-02985-6. 689
690
691
113. Dubey, V.; Kheni, D.; Sureja, V. Efficacy Evaluation of Standardized *Boswellia Serrata* Extract (Aflapin®) in Osteoarthritis: A Systematic Review and Sub-Group Meta-Analysis Study. *EXPLORE* **2024**, *20*, 102983, doi:10.1016/j.explore.2024.02.001. 692
693
694
114. Vaidya, N.; Agarwal, R.; Dipankar, D.G.; Patkar, H.; Ganu, G.; Nagore, D.; Godse, C.; Mehta, A.; Mehta, D.; Nair, S. Efficacy and Safety of Boswellia Serrata and Apium Graveolens L. Extract Against Knee Osteoarthritis and Cartilage Degeneration: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Trial. *Pharm Res* **2025**, *42*, 249–269, doi:10.1007/s11095-025-03818-2. 695
696
697
698
115. Siddiqui, M.Z. Boswellia Serrata, A Potential Antiinflammatory Agent: An Overview. *Indian J Pharm Sci* **2011**, *73*, 255–261, doi:10.4103/0250-474X.93507. 699
700
116. Umar, S.; Umar, K.; Sarwar, A.H.Md.G.; Khan, A.; Ahmad, N.; Ahmad, S.; Katiyar, C.K.; Husain, S.A.; Khan, H.A. *Boswellia Serrata* Extract Attenuates Inflammatory Mediators and Oxidative Stress in Collagen Induced Arthritis. *Phytomedicine* **2014**, *21*, 847–856, doi:10.1016/j.phymed.2014.02.001. 701
702
703
117. Surjushe, A.; Vasani, R.; Saple, D.G. Aloe Vera: A Short Review. *Indian J Dermatol* **2008**, *53*, 163–166, doi:10.4103/0019-5154.44785. 704
705
118. Matei, C.E.; Visan, A.I.; Cristescu, R. Aloe Vera Polysaccharides as Therapeutic Agents: Benefits Versus Side Effects in Biomedical Applications. *Polysaccharides* **2025**, *6*, 36, doi:10.3390/polysaccharides6020036. 706
707
119. Brandão, M.L.; Reis, P.R.M.; Araújo, L.A. de; Araújo, A.C.V.; Santos, M.H. de A.S.; Miguel, M.P. Evaluation of Wound Healing Treated with Latex Derived from Rubber Trees and Aloe Vera Extract in Rats. *Acta Cir Bras* **2016**, *31*, 570–577, doi:10.1590/S0102-865020160090000001. 708
709
710
120. Kim, S.-H.; Shim, K.-S.; Song, Y.; Kim, K.; Park, C.-S.; Lee, C.-K. Pharmacological and Therapeutic Activities of Aloe Vera and Its Major Active Constituent Acemannan. *Food Supplements and Biomaterials for Health* **2023**, *3*, doi:10.52361/fsbh.2023.3.e8. 711
712
713

121. Hekmatpou, D.; Mehrabi, F.; Rahzani, K.; Aminian, A. The Effect of Aloe Vera Clinical Trials on Prevention and Healing of Skin Wound: A Systematic Review. *Iran J Med Sci* **2019**, *44*, 1–9. 714 715
122. Jimenez-Garcia, C.; Perula-de Torres, L.A.; Villegas-Becerril, E.; Muñoz-Gavilan, J.J.; Espinosa-Calvo, M.; Montes-Redondo, G.; Romero-Rodriguez, E. Efficacy of an Aloe Vera, Chamomile, and Thyme Cosmetic Cream for the Prophylaxis and Treatment of Mild Dermatitis Induced by Radiation Therapy in Breast Cancer Patients: A Controlled Clinical Trial (Alantel Trials). *Trials* **2024**, *25*, 84, doi:10.1186/s13063-024-07901-8. 716 717 718 719
123. Tanaka, M.; Yamamoto, Y.; Misawa, E.; Nabeshima, K.; Saito, M.; Yamauchi, K.; Abe, F.; Furukawa, F. Effects of Aloe Sterol Supplementation on Skin Elasticity, Hydration, and Collagen Score: A 12-Week Double-Blind, Randomized, Controlled Trial. *Skin Pharmacol Physiol* **2017**, *29*, 309–317, doi:10.1159/000454718. 720 721 722
124. Kaminaka, C.; Yamamoto, Y.; Sakata, M.; Hamamoto, C.; Misawa, E.; Nabeshima, K.; Saito, M.; Tanaka, M.; Abe, F.; Jinnin, M. Effects of Low-dose Aloe Sterol Supplementation on Skin Moisture, Collagen Score and Objective or Subjective Symptoms: 12-week, Double-blind, Randomized Controlled Trial. *J Dermatol* **2020**, *47*, 998–1006, doi:10.1111/1346-8138.15428. 723 724 725 726
125. Haque, S.D.; Saha, S.K.; Salma, U.; Nishi, M.K.; Rahaman, M.S. Antibacterial Effect of Aloe Vera (Aloe Barbadensis) Leaf Gel against Staphylococcus Aureus, Pseudomonas Aeruginosa, Escherichia Coli and Klebsiella Pneumoniae. *Mymensingh Med J* **2019**, *28*, 490–496. 727 728 729
126. Reuter, J.; Jocher, A.; Stump, J.; Grossjohann, B.; Franke, G.; Schempp, C.M. Investigation of the Anti-Inflammatory Potential of Aloe Vera Gel (97.5%) in the Ultraviolet Erythema Test. *Skin Pharmacol Physiol* **2008**, *21*, 106–110, doi:10.1159/000114871. 730 731 732
127. Barbalho, S.M.; de Sousa Gonzaga, H.F.; de Souza, G.A.; de Alvares Goulart, R.; de Sousa Gonzaga, M.L.; de Alvarez Rezende, B. Dermatological Effects of Curcuma Species: A Systematic Review. *Clin Exp Dermatol* **2021**, *46*, 825–833, doi:10.1111/ced.14584. 733 734 735
128. Kim, J.H.; Gupta, S.C.; Park, B.; Yadav, V.R.; Aggarwal, B.B. Turmeric (Curcuma Longa) Inhibits Inflammatory Nuclear Factor (NF)- κ B and NF- κ B-Regulated Gene Products and Induces Death Receptors Leading to Suppressed Proliferation, Induced Chemosensitization, and Suppressed Osteoclastogenesis. *Mol Nutr Food Res* **2012**, *56*, 454–465, doi:10.1002/mnfr.201100270. 736 737 738 739
129. Mo, Z.; Yuan, J.; Guan, X.; Peng, J. Advancements in Dermatological Applications of Curcumin: Clinical Efficacy and Mechanistic Insights in the Management of Skin Disorders. *Clin Cosmet Investig Dermatol* **2024**, *17*, 1083–1092, doi:10.2147/CCID.S467442. 740 741 742
130. Nie, Y.; Li, Y. Curcumin: A Potential Anti-Photoaging Agent. *Front Pharmacol* **2025**, *16*, 1559032, doi:10.3389/fphar.2025.1559032. 743 744
131. Chaudhari, S.P.; Tam, A.Y.; Barr, J.A. Curcumin. *J Clin Aesthet Dermatol* **2015**, *8*, 43–48. 745
132. Buhmann, C.; Mobasheri, A.; Busch, F.; Aldinger, C.; Stahlmann, R.; Montaseri, A.; Shakibaei, M. Curcumin Modulates Nuclear Factor κ B (NF- κ B)-Mediated Inflammation in Human Tenocytes in Vitro. *J Biol Chem* **2011**, *286*, 28556–28566, doi:10.1074/jbc.M111.256180. 746 747 748
133. WU, J.; DENG, L.; YIN, L.; MAO, Z.; GAO, X. Curcumin Promotes Skin Wound Healing by Activating Nrf2 Signaling Pathways and Inducing Apoptosis in Mice. *Turk J Med Sci* **53**, 1127–1135, doi:10.55730/1300-0144.5678. 749 750
134. Givol, O.; Kornhaber, R.; Visentin, D.; Cleary, M.; Haik, J.; Harats, M. A Systematic Review of Calendula Officinalis Extract for Wound Healing. *Wound Repair Regen* **2019**, *27*, 548–561, doi:10.1111/wrr.12737. 751 752
135. Parente, L.M.L.; Lino Júnior, R. de S.; Tresvenzol, L.M.F.; Vinaud, M.C.; de Paula, J.R.; Paulo, N.M. Wound Healing and Anti-Inflammatory Effect in Animal Models of Calendula Officinalis L. Growing in Brazil. *Evid Based Complement Alternat Med* **2012**, *2012*, 375671, doi:10.1155/2012/375671. 753 754 755
136. Silva, D.; Ferreira, M.S.; Sousa-Lobo, J.M.; Cruz, M.T.; Almeida, I.F. Anti-Inflammatory Activity of Calendula Officinalis L. Flower Extract. *Cosmetics* **2021**, *8*, 31, doi:10.3390/cosmetics8020031. 756 757

137. Sapkota, B.; Kunwar, P. A Review on Traditional Uses, Phytochemistry and Pharmacological Activities of *Calendula Officinalis* Linn. *Natural Product Communications* **2024**, *19*, 1934578X241259021, doi:10.1177/1934578X241259021. 758
759
760
138. Giostri, G.S.; Novak, E.M.; Buzzi, M.; Guarita-Souza, L.C. Treatment of Acute Wounds in Hand with *Calendula Officinalis* L.: A Randomized Trial. *Tissue Barriers* **2021**, *10*, 1994822, doi:10.1080/21688370.2021.1994822. 761
762
139. Siddiquee, S.; McGee, M.A.; Vincent, A.D.; Giles, E.; Clothier, R.; Carruthers, S.; Penniment, M. Efficacy of Topical *Calendula Officinalis* on Prevalence of Radiation-Induced Dermatitis: A Randomised Controlled Trial. *Australas J Dermatol* **2021**, *62*, e35–e40, doi:10.1111/ajd.13434. 763
764
765
140. Dinda, M.; Mazumdar, S.; Das, S.; Ganguly, D.; Dasgupta, U.B.; Dutta, A.; Jana, K.; Karmakar, P. The Water Fraction of *Calendula Officinalis* Hydroethanol Extract Stimulates In Vitro and In Vivo Proliferation of Dermal Fibroblasts in Wound Healing. *Phytother Res* **2016**, *30*, 1696–1707, doi:10.1002/ptr.5678. 766
767
768
141. Chopade, V.; Phatak, A.; Upaganlawar, A.; Tankar, A. Green Tea (*Camellia Sinensis*): Chemistry, Traditional, Medicinal Uses and Its Pharmacological Activities- A Review. *Pharmacognosy Review* **2008**, *2*, 157–162. 769
770
142. Xu, L.; Xia, G.; Luo, Z.; Liu, S. UHPLC Analysis of Major Functional Components in Six Types of Chinese Teas: Constituent Profile and Origin Consideration. *LWT* **2019**, *102*, 52–57, doi:10.1016/j.lwt.2018.12.008. 771
772
143. Yoon, J.Y.; Kwon, H.H.; Min, S.U.; Thiboutot, D.M.; Suh, D.H. Epigallocatechin-3-Gallate Improves Acne in Humans by Modulating Intracellular Molecular Targets and Inhibiting P. Acnes. *J Invest Dermatol* **2013**, *133*, 429–440, doi:10.1038/jid.2012.292. 773
774
775
144. Naveed, M.; BiBi, J.; Kamboh, A.A.; Suheryani, I.; Kakar, I.; Fazlani, S.A.; FangFang, X.; kalhoro, S.A.; Yunjuan, L.; Kakar, M.U.; et al. Pharmacological Values and Therapeutic Properties of Black Tea (*Camellia Sinensis*): A Comprehensive Overview. *Biomedicine & Pharmacotherapy* **2018**, *100*, 521–531, doi:10.1016/j.biopha.2018.02.048. 776
777
778
145. Zhao, T.; Li, C.; Wang, S.; Song, X. Green Tea (*Camellia Sinensis*): A Review of Its Phytochemistry, Pharmacology, and Toxicology. *Molecules* **2022**, *27*, 3909, doi:10.3390/molecules27123909. 779
780
146. Kim, S.; Park, T.H.; Kim, W.I.; Park, S.; Kim, J.H.; Cho, M.K. The Effects of Green Tea on Acne Vulgaris: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Phytother Res* **2021**, *35*, 374–383, doi:10.1002/ptr.6809. 781
782
783
147. Mahmood, T.; Akhtar, N.; Khan, B.A.; Khan, H.M.S.; Saeed, T. Outcomes of 3% Green Tea Emulsion on Skin Sebum Production in Male Volunteers. *Bosn J Basic Med Sci* **2010**, *10*, 260–264, doi:10.17305/bjbms.2010.2697. 784
785
148. Kim, M.J.; Yang, Y.J.; Min, G.-Y.; Heo, J.W.; Son, J.D.; You, Y.Z.; Kim, H.H.; Kim, G.S.; Lee, H.-J.; Yang, J.-H.; et al. Anti-Inflammatory and Antioxidant Properties of *Camellia Sinensis* L. Extract as a Potential Therapeutic for Atopic Dermatitis through NF- κ B Pathway Inhibition. *Sci Rep* **2025**, *15*, 2371, doi:10.1038/s41598-025-86678-5. 786
787
788
149. Zheng, X.-Q.; Zhang, X.-H.; Gao, H.-Q.; Huang, L.-Y.; Ye, J.-J.; Ye, J.-H.; Lu, J.-L.; Ma, S.-C.; Liang, Y.-R. Green Tea Catechins and Skin Health. *Antioxidants (Basel)* **2024**, *13*, 1506, doi:10.3390/antiox13121506. 789
790
150. Shill, D.D.; Stade, H.N.; Goodson, K.C.; Beltran, M.A.; Haller, D.; Benson, M.; Drumwright, M.D.; Scholz, D. Pleiotropic Effects of a *Camellia Sinensis* Leaf Extract on in Vitro and in Vivo Skin Health Characteristics. *Int J Cosmet Sci* **2025**, *47*, 835–850, doi:10.1111/ics.13073. 791
792
793
151. Maron, J.L.; Elmendorf, S.C.; Vilà, M. CONTRASTING PLANT PHYSIOLOGICAL ADAPTATION TO CLIMATE IN THE NATIVE AND INTRODUCED RANGE OF *HYPERICUM PERFORATUM*. *Evol* **2007**, *61*, 1912–1924, doi:10.1111/j.1558-5646.2007.00153.x. 794
795
796
152. Nobakht, S.Z.; Akaberi, M.; Mohammadpour, A.H.; Tafazoli Moghadam, A.; Emami, S.A. *Hypericum Perforatum*: Traditional Uses, Clinical Trials, and Drug Interactions. *Iran J Basic Med Sci* **2022**, *25*, 1045–1058, doi:10.22038/IJBMS.2022.65112.14338. 797
798
799

153. Zhang, R.; Ji, Y.; Zhang, X.; Kennelly, E.J.; Long, C. Ethnopharmacology of *Hypericum* Species in China: A Comprehensive Review on Ethnobotany, Phytochemistry and Pharmacology. *Journal of Ethnopharmacology* **2020**, *254*, 112686, doi:10.1016/j.jep.2020.112686.
154. Alahmad, A.; Alghoraibi, I.; Zein, R.; Kraft, S.; Dräger, G.; Walter, J.-G.; Scheper, T. Identification of Major Constituents of *Hypericum Perforatum* L. Extracts in Syria by Development of a Rapid, Simple, and Reproducible HPLC-ESI-Q-TOF MS Analysis and Their Antioxidant Activities. *ACS Omega* **2022**, *7*, 13475–13493, doi:10.1021/acsomega.1c06335.
155. Wölfle, U.; Seelinger, G.; Schempp, C.M. Topical Application of St. John's Wort (*Hypericum Perforatum*). *Planta Med* **2014**, *80*, 109–120, doi:10.1055/s-0033-1351019.
156. Schempp, C.M.; Windeck, T.; Hezel, S.; Simon, J.C. Topical Treatment of Atopic Dermatitis with St. John's Wort Cream--a Randomized, Placebo Controlled, Double Blind Half-Side Comparison. *Phytomedicine* **2003**, *10 Suppl 4*, 31–37, doi:10.1078/1433-187x-00306.
157. Kacerovská, D.; Pizinger, K.; Majer, F.; Šmíd, F. Photodynamic Therapy of Nonmelanoma Skin Cancer with Topical *Hypericum Perforatum* Extract—A Pilot Study. *Photochemistry and Photobiology* **2008**, *84*, 779–785, doi:10.1111/j.1751-1097.2007.00260.x.
158. Samadi, S.; Khadivzadeh, T.; Emami, A.; Moosavi, N.S.; Tafaghodi, M.; Behnam, H.R. The Effect of *Hypericum Perforatum* on the Wound Healing and Scar of Cesarean. *The Journal of Alternative and Complementary Medicine* **2010**, *16*, 113–117, doi:10.1089/acm.2009.0317.
159. Clewell, A.; Barnes, M.; Endres, J.R.; Ahmed, M.; Ghambeer, D.K.S. Efficacy and Tolerability Assessment of a Topical Formulation Containing Copper Sulfate and *Hypericum Perforatum* on Patients with Herpes Skin Lesions: A Comparative, Randomized Controlled Trial. *J Drugs Dermatol* **2012**, *11*, 209–215.
160. Farasati Far, B.; Gouranmohit, G.; Naimi-jamal, M.R.; Neysani, E.; El-Nashar, H.A.S.; El-Shazly, M.; Khoshnevisan, K. The Potential Role of *Hypericum Perforatum* in Wound Healing: A Literature Review on the Phytochemicals, Pharmacological Approaches, and Mechanistic Perspectives. *Phytotherapy Research* **2024**, *38*, 3271–3295, doi:10.1002/ptr.8204.
161. Potenza, M.A.; Montagnani, M.; Santacroce, L.; Charitos, I.A.; Bottalico, L. Ancient Herbal Therapy: A Brief History of *Panax Ginseng*. *J Ginseng Res* **2023**, *47*, 359–365, doi:10.1016/j.jgr.2022.03.004.
162. Xiang, Y.-Z.; Shang, H.-C.; Gao, X.-M.; Zhang, B.-L. A Comparison of the Ancient Use of *Ginseng* in Traditional Chinese Medicine with Modern Pharmacological Experiments and Clinical Trials. *Phytotherapy Research* **2008**, *22*, 851–858, doi:10.1002/ptr.2384.
163. Ogawa-Ochiai, K.; Kawasaki, K. *Panax Ginseng* for Frailty-Related Disorders: A Review. *Front. Nutr.* **2019**, *5*, doi:10.3389/fnut.2018.00140.
164. Sutopo, N.C.; Qomaladewi, N.P.; Lee, H.W.; Lee, M.S.; Kim, J.H.; Cho, J.Y. Comprehensive Understanding and Underlying Molecular Mechanisms of the Adaptogenic Effects of *Panax Ginseng*. *Journal of Ginseng Research* **2025**, *49*, 356–365, doi:10.1016/j.jgr.2025.03.013.
165. Liu, H.; Lu, X.; Hu, Y.; Fan, X. Chemical Constituents of *Panax Ginseng* and *Panax Notoginseng* Explain Why They Differ in Therapeutic Efficacy. *Pharmacological Research* **2020**, *161*, 105263, doi:10.1016/j.phrs.2020.105263.
166. Kim, S.H.; Park, K.S.; Chang, M.J.; Sung, J.H. Effects of *Panax Ginseng* Extract on Exercise-Induced Oxidative Stress. *J Sports Med Phys Fitness* **2005**, *45*, 178–182.
167. Kim, H.-G.; Cho, J.-H.; Yoo, S.-R.; Lee, J.-S.; Han, J.-M.; Lee, N.-H.; Ahn, Y.-C.; Son, C.-G. Antifatigue Effects of *Panax Ginseng* C.A. Meyer: A Randomised, Double-Blind, Placebo-Controlled Trial. *PLoS One* **2013**, *8*, e61271, doi:10.1371/journal.pone.0061271.

168. Zhu, J.; Xu, X.; Zhang, X.; Zhuo, Y.; Chen, S.; Zhong, C.; Liu, M.; Wang, Z. Efficacy of Ginseng Supplements on Disease-Related Fatigue: A Systematic Review and Meta-Analysis. *Medicine (Baltimore)* **2022**, *101*, e29767, doi:10.1097/MD.00000000000029767. 842
843
844
169. Flanagan, S.D.; DuPont, W.H.; Caldwell, L.K.; Hardesty, V.H.; Barnhart, E.C.; Beeler, M.K.; Post, E.M.; Volek, J.S.; Kraemer, W.J. The Effects of a Korean Ginseng, GINST15, on Hypo-Pituitary-Adrenal and Oxidative Activity Induced by Intense Work Stress. *J Med Food* **2018**, *21*, 104–112, doi:10.1089/jmf.2017.0071. 845
846
847
170. Dormal, V.; Jonniaux, L.; Buchet, M.; Simar, L.; Copine, S.; Deldicque, L. Effect of Hydroponically Grown Red Panax Ginseng on Perceived Stress Level, Emotional Processing, and Cognitive Functions in Moderately Stressed Adults: A Randomized, Double-Blind, Placebo-Controlled Study. *Nutrients* **2025**, *17*, 955, doi:10.3390/nu17060955. 848
849
850
171. Reay, J.L.; Kennedy, D.O.; Scholey, A.B. Single Doses of Panax Ginseng (G115) Reduce Blood Glucose Levels and Improve Cognitive Performance during Sustained Mental Activity. *J Psychopharmacol* **2005**, *19*, 357–365, doi:10.1177/0269881105053286. 851
852
853
172. Reay, J.L.; Kennedy, D.O.; Scholey, A.B. Effects of Panax Ginseng, Consumed with and without Glucose, on Blood Glucose Levels and Cognitive Performance during Sustained “mentally Demanding” Tasks. *J Psychopharmacol* **2006**, *20*, 771–781, doi:10.1177/0269881106061516. 854
855
856
173. Reay, J.L.; Scholey, A.B.; Kennedy, D.O. Panax Ginseng (G115) Improves Aspects of Working Memory Performance and Subjective Ratings of Calmness in Healthy Young Adults. *Human Psychopharmacology: Clinical and Experimental* **2010**, *25*, 462–471, doi:10.1002/hup.1138. 857
858
859
174. Jin, Y.; Cui, R.; Zhao, L.; Fan, J.; Li, B. Mechanisms of Panax Ginseng Action as an Antidepressant. *Cell Prolif* **2019**, *52*, e12696, doi:10.1111/cpr.12696. 860
861
175. Panossian, A.; Wikman, G.; Sarris, J. Rosenroot (*Rhodiola Rosea*): Traditional Use, Chemical Composition, Pharmacology and Clinical Efficacy. *Phytomedicine* **2010**, *17*, 481–493, doi:10.1016/j.phymed.2010.02.002. 862
863
176. Ivanova Stojcheva, E.; Quintela, J.C. The Effectiveness of *Rhodiola Rosea* L. Preparations in Alleviating Various Aspects of Life-Stress Symptoms and Stress-Induced Conditions—Encouraging Clinical Evidence. *Molecules* **2022**, *27*, 3902, doi:10.3390/molecules27123902. 864
865
866
177. Xu, W.; Yang, T.; Zhang, J.; Li, H.; Guo, M. *Rhodiola Rosea*: A Review in the Context of PPPM Approach. *EPMA J* **2024**, *15*, 233–259, doi:10.1007/s13167-024-00367-3. 867
868
178. Darbinyan, V.; Kteyan, A.; Panossian, A.; Gabrielian, E.; Wikman, G.; Wagner, H. *Rhodiola Rosea* in Stress Induced Fatigue — A Double Blind Cross-over Study of a Standardized Extract SHR-5 with a Repeated Low-Dose Regimen on the Mental Performance of Healthy Physicians during Night Duty. *Phytomedicine* **2000**, *7*, 365–371, doi:10.1016/S0944-7113(00)80055-0. 869
870
871
872
179. Olsson, E.M.G.; Schéele, B. von; Panossian, A.G. A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Standardised Extract SHR-5 of the Roots of *Rhodiola Rosea* in the Treatment of Subjects with Stress-Related Fatigue. *Planta Medica* **2008**, *75*, 105–112, doi:10.1055/s-0028-1088346. 873
874
875
180. Ross, S.M. *Rhodiola Rosea* (SHR-5), Part I: A Proprietary Root Extract of *Rhodiola Rosea* Is Found to Be Effective in the Treatment of Stress-Related Fatigue. *Holist Nurs Pract* **2014**, *28*, 149–154, doi:10.1097/HNP.0000000000000014. 876
877
181. Ballmann, C.G.; Maze, S.B.; Wells, A.C.; Marshall, M.M.; Rogers, R.R. Effects of Short-Term *Rhodiola Rosea* (Golden Root Extract) Supplementation on Anaerobic Exercise Performance. *J Sports Sci* **2019**, *37*, 998–1003, doi:10.1080/02640414.2018.1538028. 878
879
880
182. Marcos-Frutos, D.; Leban, Ž.; Li, Z.; Zhang, X.; Lara, P.M.; Alix-Fages, C.; Jiménez-Martínez, P.; Zebboudji, N.; Caillet, A.; Redondo, B.; et al. The Impact of *Rhodiola Rosea* Extract on Strength Performance in Alternative Bench-Press and Bench-Pull Exercises Under Resting and Mental Fatigue Conditions: A Randomized, Triple-Blinded, Placebo-Controlled, Crossover Trial. *Nutrients* **2025**, *17*, 940, doi:10.3390/nu17060940. 881
882
883
884

183. Bystritsky, A.; Kerwin, L.; Feusner, J.D. A Pilot Study of *Rhodiola Rosea* (Rhodax) for Generalized Anxiety Disorder (GAD). *J Altern Complement Med* **2008**, *14*, 175–180, doi:10.1089/acm.2007.7117. 885
184. Copley, M.; Banks, A.P.; Boyle, J. The Effects of *Rhodiola Rosea* L. Extract on Anxiety, Stress, Cognition and Other Mood Symptoms. *Phytotherapy Research* **2015**, *29*, 1934–1939, doi:10.1002/ptr.5486. 886
185. Mao, J.J.; Xie, S.X.; Zee, J.; Soeller, I.; Li, Q.S.; Rockwell, K.; Amsterdam, J.D. *Rhodiola Rosea* versus Sertraline for Major Depressive Disorder: A Randomized Placebo-Controlled Trial. *Phytomedicine* **2015**, *22*, 394–399, doi:10.1016/j.phymed.2015.01.010. 888
186. Khalid, M.U.; Sultan, M.T.; Baig, I.; Abbas, A.; Noman, A.M.; Zinedine, A.; Bartkiene, E.; Rocha, J.M. A Comprehensive Review on the Bioactivity and Pharmacological Attributes of *Withania Somnifera*. *Natural Product Research* **2025**, *0*, 1–15, doi:10.1080/14786419.2025.2499070. 889
187. Paul, S.; Chakraborty, S.; Anand, U.; Dey, S.; Nandy, S.; Ghorai, M.; Saha, S.C.; Patil, M.T.; Kandimalla, R.; Proćków, J.; et al. *Withania Somnifera* (L.) Dunal (Ashwagandha): A Comprehensive Review on Ethnopharmacology, Pharmacotherapeutics, Biomedicinal and Toxicological Aspects. *Biomedicine & Pharmacotherapy* **2021**, *143*, 112175, doi:10.1016/j.biopha.2021.112175. 892
188. Mukherjee, P.K.; Banerjee, S.; Biswas, S.; Das, B.; Kar, A.; Katiyar, C.K. *Withania Somnifera* (L.) Dunal - Modern Perspectives of an Ancient Rasayana from Ayurveda. *Journal of Ethnopharmacology* **2021**, *264*, 113157, doi:10.1016/j.jep.2020.113157. 893
189. Orrù, A.; Casu, M.A.; Tambaro, S.; Marchese, G.; Casu, G.; Ruiu, S. *Withania Somnifera* (L.) Dunal Root Extract Alleviates Formalin-Induced Nociception in Mice: Involvement of the Opioidergic System. *Behav Pharmacol* **2016**, *27*, 57–68, doi:10.1097/FBP.000000000000195. 894
190. Orrù, A.; Marchese, G.; Ruiu, S. Alkaloids in *Withania Somnifera* (L.) Dunal Root Extract Contribute to Its Anti-Inflammatory Activity. *Pharmacology* **2023**, *108*, 301–307, doi:10.1159/000527656. 895
191. Saleem, S.; Muhammad, G.; Hussain, M.A.; Altaf, M.; Bukhari, S.N.A. *Withania Somnifera* L.: Insights into the Phytochemical Profile, Therapeutic Potential, Clinical Trials, and Future Prospective. *Iran J Basic Med Sci* **2020**, *23*, 1501–1526, doi:10.22038/IJBMS.2020.44254.10378. 896
192. Sonar, V.P.; Fois, B.; Distinto, S.; Maccioni, E.; Meleddu, R.; Cottiglia, F.; Acquas, E.; Kasture, S.; Floris, C.; Colombo, D.; et al. Ferulic Acid Esters and Withanolides: In Search of *Withania Somnifera* GABAA Receptor Modulators. *J Nat Prod* **2019**, *82*, 1250–1257, doi:10.1021/acs.jnatprod.8b01023. 897
193. Maccioni, R.; Serra, M.; Marongiu, J.; Cottiglia, F.; Maccioni, E.; Bassareo, V.; Morelli, M.; Kasture, S.B.; Acquas, E. Effects of Docosanyl Ferulate, a Constituent of *Withania Somnifera*, on Ethanol- and Morphine-Elicited Conditioned Place Preference and ERK Phosphorylation in the Accumbens Shell of CD1 Mice. *Psychopharmacology (Berl)* **2022**, *239*, 795–806, doi:10.1007/s00213-022-06069-w. 898
194. Wankhede, S.; Langade, D.; Joshi, K.; Sinha, S.R.; Bhattacharyya, S. Examining the Effect of *Withania Somnifera* Supplementation on Muscle Strength and Recovery: A Randomized Controlled Trial. *J Int Soc Sports Nutr* **2015**, *12*, 43, doi:10.1186/s12970-015-0104-9. 899
195. Ziegenfuss, T.N.; Kedia, A.W.; Sandrock, J.E.; Raub, B.J.; Kerksick, C.M.; Lopez, H.L. Effects of an Aqueous Extract of *Withania Somnifera* on Strength Training Adaptations and Recovery: The STAR Trial. *Nutrients* **2018**, *10*, 1807, doi:10.3390/nu10111807. 900
196. Verma, N.; Gupta, S.K.; Patil, S.; Tiwari, S.; Mishra, A.K. Effects of Ashwagandha (*Withania Somnifera*) Standardized Root Extract on Physical Endurance and VO₂max in Healthy Adults Performing Resistance Training: An Eight-Week, Prospective, Randomized, Double-Blind, Placebo-Controlled Study. *F1000Res* **2024**, *12*, 335, doi:10.12688/f1000research.130932.2. 901

197. Coope, O.C.; Reales Salguero, A.; Spurr, T.; Páez Calvente, A.; Domenech Farre, A.; Jordán Fisas, E.; Lloyd, B.; Gooderick, J.; Abad Sangrà, M.; Roman-Viñas, B. Effects of Root Extract of Ashwagandha (*Withania Somnifera*) on Perception of Recovery and Muscle Strength in Female Athletes. *Eur J Sport Sci* **2025**, *25*, e12265, doi:10.1002/ejsc.12265.
198. Biswal, B.M.; Sulaiman, S.A.; Ismail, H.C.; Zakaria, H.; Musa, K.I. Effect of *Withania Somnifera* (Ashwagandha) on the Development of Chemotherapy-Induced Fatigue and Quality of Life in Breast Cancer Patients. *Integr Cancer Ther* **2013**, *12*, 312–322, doi:10.1177/1534735412464551.
199. Lopresti, A.L.; Drummond, P.D.; Smith, S.J. A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Examining the Hormonal and Vitality Effects of Ashwagandha (*Withania Somnifera*) in Aging, Overweight Males. *Am J Mens Health* **2019**, *13*, 1557988319835985, doi:10.1177/1557988319835985.
200. Smith, S.J.; Lopresti, A.L.; Fairchild, T.J. Exploring the Efficacy and Safety of a Novel Standardized Ashwagandha (*Withania Somnifera*) Root Extract (Witholytin®) in Adults Experiencing High Stress and Fatigue in a Randomized, Double-Blind, Placebo-Controlled Trial. *J Psychopharmacol* **2023**, *37*, 1091–1104, doi:10.1177/02698811231200023.
201. Choudhary, D.; Bhattacharyya, S.; Bose, S. Efficacy and Safety of Ashwagandha (*Withania Somnifera* (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions. *Journal of Dietary Supplements* **2017**, *14*, 599–612, doi:10.1080/19390211.2017.1284970.
202. Leonard, M.; Dickerson, B.; Estes, L.; Gonzalez, D.E.; Jenkins, V.; Johnson, S.; Xing, D.; Yoo, C.; Ko, J.; Purpura, M.; et al. Acute and Repeated Ashwagandha Supplementation Improves Markers of Cognitive Function and Mood. *Nutrients* **2024**, *16*, 1813, doi:10.3390/nu16121813.
203. Chandrasekhar, K.; Kapoor, J.; Anishetty, S. A Prospective, Randomized Double-Blind, Placebo-Controlled Study of Safety and Efficacy of a High-Concentration Full-Spectrum Extract of Ashwagandha Root in Reducing Stress and Anxiety in Adults. *Indian J Psychol Med* **2012**, *34*, 255–262, doi:10.4103/0253-7176.106022.
204. Lopresti, A.L.; Smith, S.J.; Malvi, H.; Kodgule, R. An Investigation into the Stress-Relieving and Pharmacological Actions of an Ashwagandha (*Withania Somnifera*) Extract. *Medicine (Baltimore)* **2019**, *98*, e17186, doi:10.1097/MD.00000000000017186.
205. Pandit, S.; Srivastav, A.K.; Sur, T.K.; Chaudhuri, S.; Wang, Y.; Biswas, T.K. Effects of *Withania Somnifera* Extract in Chronically Stressed Adults: A Randomized Controlled Trial. *Nutrients* **2024**, *16*, 1293, doi:10.3390/nu16091293.
206. Sprengel, M.; Laskowski, R.; Jost, Z. *Withania Somnifera* (Ashwagandha) Supplementation: A Review of Its Mechanisms, Health Benefits, and Role in Sports Performance. *Nutrition & Metabolism* **2025**, *22*, 9, doi:10.1186/s12986-025-00902-7.

956

957